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Theranostic nanostructures are those that have both therapeutic as well as 
diagnostic function, e.g., due to having a combination of drugs as well as imaging agents 
in them. Such structures, especially those that can selectively home in on cancer tumors, 
have received considerable attention recently. Although many different structures have 
been synthesized, their complexity, high cost, and poor biocompatibility have limited 
their clinical application. In this study, we focus on creating new classes of theranostic 
nanostructures using simple routes (via self-assembly) and utilizing inexpensive and 
biocompatible materials. 
In our first study, we describe a class of liposomal probes that can allow certain 
tumors to be imaged by magnetic resonance imaging (MRI). Tumors, such as those of 
 
 
head and neck cancer, are known to over-express the epidermal growth factor receptor 
(EGFR). Our liposomal probes bear anti-EGFR antibodies as well as chelated gadolinium 
(Gd), a positive (image-brightening) contrast agent for MRI. To synthesize these probes, 
we use a strategy that is carefully designed to be simple and scalable: it employs two 
steps that each involve self-assembly. The resulting probes bind in vitro to EGFR-
overexpressing tumor cells compared to controls. Moreover, cancer cells with bound 
probes can be tracked by MRI. In the future, these probes could find clinical use for 
tracking the efficacy of cancer treatment in real-time. 
Next, we report a class of microscale (3 to 5 µm) containers derived from 
erythrocytes (red blood cells). Micro-erythrosomes (MERs) are produced by emptying 
the inner contents of these cells and resuspending the empty structures in buffer. We have 
developed procedures to functionalize the surfaces of the MERs with targeting moieties 
(such as anti-EGFR antibodies) and also to load solutes (such as fluorescent dyes and 
MRI contrast agents) into the cores of the MERs. Thus, we show that MERs are a 
versatile class of microparticles for biomedical applications. 
In our final study, we show that the MERs from the previous study can be 
sonicated to yield nanoscale structures, termed nano-erythrosomes (NERs), with average 
sizes around 120 nm. NERs are membrane-covered nanoscale containers, much like 
liposomes. They show excellent colloidal stability in both buffer as well as in serum, and 
they are able to withstand freeze-thaw cycling. Moreover, NER membranes can be 
decorated with fluorescent markers and antibodies, solutes can be encapsulated in the 
cores of the NERs, and NERs can be targeted towards mammalian cells. Thus, NERs are 
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Introduction and Overview 
 
1.1. Problem Description and Motivation 
This dissertation is devoted to the development of “theranostic” nanostructures. 
The term “theranostic” is a combination of the words “therapeutic” and “diagnostic”. It 
thus refers to nanostructures that can have therapeutic function, i.e., in treating diseases 
like cancer, as well as diagnostic capabilities, i.e., in analyzing the presence or extent of 
the disease. Current research in nanomedicine is increasingly focusing on such types of 
multifunctional agents, and the work done here is a step in that direction.  
  
Development of nanoscale therapeutics with specificity for targeting cancerous 
cells without harming normal tissues is of great significance in cancer treatment. Such 
therapeutics provide new directions and hope for eradicating tumors. To optimize the 
efficacy of therapeutic efforts, it is advantageous to monitor the progression of the 
disease in real time. This is where diagnostic agents and imaging techniques come into 
play. Computed tomography (CT), positron emission tomography (PET), and magnetic 
resonance imaging (MRI) are the most useful live imaging technologies for cancer 
evaluation.1 Among these methods, MRI is emerging as a preferred imaging technique. 
MRI is advantageous in that it provides high-resolution details and better contrast for 
discriminating between normal and tumor tissue, especially when used in conjunction 




Contrast agents for MRI fall into two categories: negative-contrast (image-
darkening) agents like iron oxide and positive-contrast (image-brightening) agents, such 
as gadolinium (Gd). Negative-contrast agents yield dark signals on images, often making 
it difficult to differentiate the tumor from air passages in images. In comparison, positive-
contrast agents like Gd3+ produce signal enhancement. Gd3+ is a paramagnetic ion that 
shortens the T1 and T2 relaxation times of nearby water protons, thereby providing an 
increased signal on the MR image.2-4 Because Gd3+ is toxic, it is often used in the clinic 
in a chelated form, where the cation is bound to a cage-like anion. 
 
An example of a theranostic nanoparticle for cancer treatment is one that has the 
following constituents: (a) therapeutic drugs in the particle core or attached to its surface; 
(b) diagnostic moieties like chelated gadolinium, either in the core or attached to its 
surface; and (c) a targeting moiety to allow the particle to home in to the site of the 
tumor. Such a particle would potentially accumulate at the site of the tumor and deliver 
its payload (drugs), while at the same time allowing the tumor to be visualized by MRI.  
 
While the potential for nanoparticles in cancer treatment is enormous, currently 
there are very few examples of these particles being used by doctors in the clinic. There 
are many reasons for this, including the fact that these particles are very costly and 
difficult to prepare, often exhibit limited stability under long-term storage, and also 
exhibit rather high levels of toxicity to humans. The long-term motivation for our work is 
to put forward new kinds of nanoparticles that can address some of the above concerns 
and thereby emerge as viable candidates for eventual clinical applications.   
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1.2. Proposed Approach 
In this dissertation, we will describe three classes of nanoparticles that have 
potential for theranostic applications. Each of these nanoparticles has a lipid membrane 
surrounding an aqueous core; thus, each of them resembles the structure of a biological 
cell. Importantly, the nanoparticles are assembled and held together as a result of 
non-covalent (weak) interactions rather than by covalent bonds: this process is termed 
“self-assembly”. We believe that such self-assembled nanoparticles made from lipids can 
be relatively cost-effective, easy to prepare, and exhibit a high degree of biocompatibility 
(low toxicity). Therefore, the particles can be attractive candidates for eventual use in the 
clinic. The three classes of nanoparticles are described in further detail below. 
 
1.2.1. Liposomes 
First, in Chapter 3, we describe a class of liposomes conjugated with chelated Gd 
as well as antibodies to the epidermal growth factor receptor (EGFR). EGFRs are known 
to be overexpressed on the membranes of certain tumors. Therefore, anti-EGFR 
antibodies serve as targeting agents and allow the liposomes to home in to the locations 
of tumors. In addition, these antibodies also have a therapeutic effect because their 
binding to the cells eliminates downstream signaling pathways and thereby slows or 
eliminates the proliferation of the cancer. The presence of Gd on the liposomes also 
allows the tumor to be imaged using MRI. Thus, the liposomes in this study serve as 
theranostic agents. A notable feature of our synthesis method in this study lies in its 
simplicity. We use self-assembly to conjugate the Gd and antibody to the liposome, 
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unlike previous studies that have required various chemical reactions to perform such 
conjugation. Thus, our approach is simple, biocompatible, and one that will scale easily. 
 
1.2.2. Micro-Erythrosomes (MERs) 
In Chapter 4, we focus on micro-sized particles derived from erythrocytes or red 
blood cells (RBCs). These are termed micro-erythrosomes (MERs) with sizes ranging 
from 3 to 5 µm, and they are produced by emptying the inner contents of RBCs 
(specifically hemoglobin) and resuspending the empty structures in buffer. Although the 
ability to form MERs has been known for decades, very little is known about these 
structures, and they currently find limited use. We have developed a systematic procedure 
to convert RBCs into MERs and furthermore to functionalize the surfaces of the MERs 
with targeting moieties, including anti-EGFR antibodies. We have also developed a 
strategy to load solutes (such as fluorescent dyes and MRI contrast agents) into the cores 
of the MERs, which can subsequently be delivered across the MER membrane. Thus, we 
show that MERs can be a class of particles that are biocompatible, inexpensive, and easy 
to prepare and optimize for applications.   
 
1.2.3. Nano-Erythrosomes (NERs) 
In Chapter 5, we further expand on the erythrosome system from Chapter 4. 
Because the MERs are microscale structures, they are too large to enter mammalian cells. 
We have found that, by shearing the MERs, we can reduce their size to the nanoscale 
(~ 100 nm), thereby generating nano-erythrosomes (NERs). The NERs are analagous to 
the liposomes from Chapter 3, although very little is known about them in the literature. 
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Here, for the first time, we undertake a systematic study into their colloidal properties. 
We find that NERs are very stable to aggregation or fusion compared to conventional 
liposomes, and are able to withstand freeze-thaw cycling. Moreover, much like 
conventional liposomes, drugs can be encapsulated in the cores of NERs, and NER 
membranes can be decorated with fluorescent markers or with anti-EGFR antibodies. 
Thus, NERs are a promising and versatile class of particles for use in nanomedicine.     
 
1.3. Significance of This Work 
The significance of this work is that it presents new, alternative classes of 
theranostic structures. Our focus is on preparing biocompatible structures using simple 
and inexpensive synthesis routes, and starting from readily available precursors. We use 
self-assembly rather than covalent chemical bonding to functionalize these structures 
with antibodies or other moieties. Because of the simplicity involved, the structures 
described here are potentially easier to make at large scales, and this should make them 
attractive for future applications.  
 
Also, the MERs and NERs (Chapters 4, 5) are an interesting direction that is new 
and different. Our studies have been conducted with bovine blood, but we envision these 
being extended to human blood. Thus, there is the potential for extracting blood from a 
patient and using it to make MERs and NERs, which will be entirely compatible with the 
patient without eliciting any immune response or adverse effects. Such nanostructures 
could be re-injected into the patient as theranostic agents, e.g., to track or treat cancer 






This dissertation is concerned with self-assembled theranostic particles that can deliver 
payloads to target cells. Cancer cells that overexpress markers on their surfaces can be 
targeted using antibodies to these markers. In this chapter, we will review the basics of 
cancer targeting, the fundamentals of imaging techniques, specifically MRI, the basics of 
forming self-assembled particles from lipids, and a few of the characterization techniques 
used in this work.  
 
2.1. Tumor Targeting via EGFR 
Scientists have been increasingly looking for ways to attack malfunctioned cancer 
cells without damaging normal cells, thus reducing the side effects during cancer therapy. 
For this, it is important to target the molecules specifically present on/in tumor cells, such 
as components responsible for tumorigenic signaling, rapid cell proliferation, 
angiogenesis, DNA repair, and cell migration. Once such molecules have been identified, 
monoclonal antibodies against the molecule become a powerful tool for tumor 
identification.  
 
In this regard, one signature of various human cancers such as those of the brain, 
head and neck, lung, thyroid, colon, kidney, prostate, ovarian, bladder, and breast, is over-
expression of the epidermal growth factor receptor (EGFR).5 Increased abundance of 
EGFR results in constitutive activation of EGFR signaling and is often related with tumor 
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resistance toward chemotherapy and radiotherapy. Also, EGFR signaling activated by its 
conventional ligands (e.g., EGF and TGF-) or by ionizing radiation promotes cell 
proliferation, migration, and angiogenesis, thus potentiating the metastatic risk and poor 
prognosis of these cancers (Figure 2.1).6  
 
 
Figure 2.1. Schematic illustration of EGFR mediated signal transduction. The activation 
of EGFR by its ligand or by irradiation may cause the signal transduction cascade which 
affected the cell metabolism, gene expression, proliferation and survival.1 
 
Recently, anti-EGFR monoclonal antibodies have been developed. These have 
been shown to have a direct therapeutic effect. For example, incubation of these 
antibodies with carcinoma cell lines derived from colon, breast, head and neck, stomach, 
8 
 
prostate, and kidney cancers successfully prevented cell growth and invasion.7 The 
mechanism of this anti-tumor effect is believed to be through the blocking of intracellular 
EGFR signaling. Accordingly, certain FDA-approved EGFR-targeting monoclonal 
antibodies are now used directly in the clinic for cancer treatment.  
 
One FDA-approved anti-EGFR antibody is Cetuximab, which is used to treat 
squamous cell carcinoma of the head and neck (SCCHN). Cetuximab is an engineered 
mouse/human chimeric antibody. Results from in vitro and animal studies have shown 
that Cetuximab can augment the effects of radiation and chemotherapeutics with 
increased tumor apoptosis and reduced tumor burdens.8 Clinical trials also have 
demonstrated that Cetuximab in combination with radiotherapy improves the 5-year 
overall survival rate of SCCHN patients to 46%, compared with 36% of the radiotherapy-
alone group.9 When combined with chemotherapy, Cetuximab lengthened the median 
overall survival from 7.4 to 10.1 months.10 The recommended administration schedule of 
Cetuximab for SCCHN treatment is 400 mg/m2 as an initial induction dose followed by 
250 mg/m2 as a weekly dose for a 7-week duration. 
 
2.2. Imaging Techniques during Cancer Treatment 
To trace the progression of cancer therapy in vivo, imaging techniques provide a 
viable approach. Table 2.1 compares a wide range of imaging techniques. Fluorescence 
imaging is a widely used method in molecular biology; however, its low resolution and 
short penetration depth (< 1 cm) preclude its use for cancer monitoring. These limitations 
are also applicable for bio-luminescence.1 Computed tomography (CT), positron 
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emission tomography (PET), and magnetic resonance imaging (MRI) are the most useful 
imaging technologies for cancer. They allow for quantitative imaging.  
 
 
Table 2.1. Summary of current imaging technologies. 4 
 
2.3. Magnetic Resonance Imaging (MRI) 
MRI is an imaging modality that uses a magnetic field and non-ionizing radiation 
at radio frequencies (RF) to create an image of the regions of interest, particularly of 
abnormalities in soft tissue. Compared to other imaging methods, MRI has the following 
advantages: (1) better tissue contrast for discriminating normal and tumor tissue (with the 
assistance of contrast agents), (2) higher sensitivity in detecting metastatic tumors such as 
bone, liver, and lung, and (3) lack of exposure to X-rays, thus, being less damaging to 
patients who need repeated examination and screening.11 MRI can potentially reveal 








Figure 2.2. Basic description of magnetic resonance imaging (MRI): (a) to (e). A T1 
weighted image is shown in (f).12 
 
 
Most of the MRI imaging in clinics focuses on the proton (hydrogen atom) due to 
its natural abundance in the human body. When a proton is placed in an external magnetic 
field (B0), it will stop its random spin and align to the B0 direction or longitudinal plane 
(Figure 2.1). The spins combine with B0 and generate a net magnetization vector that 
precesses around B0 at a frequency ω. The precessional frequency ω is represented by the 
Larmor equation:  
                                                  ω = γ · B0                                                       (2.1) 
Here, γ is a constant known as the gyromagnetic ratio. If an RF pulse is applied to this 
precessing net magnetization, the protons will adsorb energy and change direction. 
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Application of an RF pulse is called excitation. The drop from the high energy level to 
lower energy level is called MR relaxation, and the collective effect of this drop in energy 
creates the T1 and T2 effects (Figure 2.1e).12 Once the RF pulse is applied, a 180° flip is 
achieved, which is opposite of the magnetic field B0. The total magnetization is the sum 
of all proton magnetizations, and the magnetizations in the x-y plane are canceled out by 
the proton movement. After the RF pulse stops, the protons begin to recover back to the z 
direction, and eventually flip back to the 0° position, thus releasing all their energy. This 
is called T1 (longitudinal) relaxation. If a 90° RF pulse is applied, the protons may 
synchronize and point at the x-y plane, while the z direction is canceled out. As time goes 
on, some of the protons spin faster and scatter from the original direction and at the end, 
the protons are spread out all over the x-y plane. This is called T2 (transverse) relaxation. 
In a T1-weighted MRI image, tissues with a shorter T1 will have a higher signal intensity 
than tissues with a longer T1 (Figure 2.1f). T1-weighted contrast agents such as Gd3+ or 
Mn2+ shorten the T1 of water in tissue, resulting in an increase in signal intensity in the 
tissues where the contrast agent has accumulated.  
 
Contrast in MR images is based on the exchange of magnetization between the 
contrast agent and water protons. Contrast agents are broadly classified as negative and 
positive agents depending on whether they lead to signal loss or enhancement. 
Superparamagnetic iron-oxide nanoparticles (SPIONs) are a class of negative contrast 
(image darkening) agents for MRI. However, the negative contrast property of SPION 
has limitations in detecting tumors. For example, the tumor mass and the surrounding air 
passages embedded in tissue may both give dark signals in MR images, making it 
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difficult to differentiate the tumor. Also, SPIONs can be toxic if the Fe3+ from these 
accumulate in cells of the liver, brain, spleen, and lung.13 Another class of MRI contrast 
agents are positive contrast (image brightening) agents, such as gadolinium (Gd). The 
Gd3+ ion is a strong paramagnetic ion that shortens the T1 and T2 relaxation times of 
nearby water protons, and thereby provides an increased signal on the MR image.2-4,14 
However, free Gd3+ ions can lead to nephrotoxicity and nephrogenic systemic fibrosis 
(NSF) in patients with renal diseases. To solve this problem, Gd3+ ions are conjugated 
with chelating compounds such as diethylenetriamine-pentaacetic acid (DTPA),15,16 and 
the resulting conjugates are chemically inert and safe.17 The standard clinical injection 
dose of Gd-chelates is about 0.1-0.3 mmol/kg, which leads to an average concentration of 
0.5 mM in the extracellular space.16,18  
 
2.4. Vesicles and Liposomes 
Vesicles are self-assembled containers formed in water by lipids, surfactants, or 
block copolymers.19,20 The molecules that form vesicles are amphiphilic, with a 
hydrophilic head and hydrophobic tail(s). The shell of the vesicle is a bilayer (ca. 2-5 nm 
in thickness) of these amphiphilic molecules, with the hydrophilic heads on both sides of 
the bilayer and thereby exposed to water, while the hydrophobic tails inside the bilayer 
are shielded from water. A vesicle can be considered to form by the folding of 
amphiphilic bilayers. Vesicles with only a single bilayer (or lamella) are called 
unilamellar vesicles (ULVs), while vesicles with several concentric bilayers are called 




The folding of bilayers into vesicles tends to occur only when the bilayers are 
present at low concentration; at high concentrations, bilayers form a lamellar phase.27 The 
tendency for bilayers to fold is driven by a desire to minimize contact of the hydrophobes 
with water at the bilayer ends. Nevertheless, it is useful to remember that, at equilibrium, 
the amphiphiles usually exist as a lamellar phase; so, the vesicle state is often of limited 
stability. In other words, given sufficient time, vesicles will get disrupted and form a 
dilute lamellar phase. An important exception to this rule exists in the case of mixed 
surfactants, where vesicles can exist as equilibrium structures.21 
 
Vesicles formed from lipids are referred to as “liposomes”. The term lipid usually 
refers to amphiphiles that have a biological origin and typically, such molecules have two 
hydrophobic (acyl) tails. Lipid bilayers constitute the membranes found at the boundary 
of every living cell as well as many intracellular organelles. The classification of lipids is 
done based on their headgroup type: for example, phospholipids have a phosphate moiety 
in their headgroup. Among the phospholipids, the phosphatidylcholines or lecithins are a 
common variety.  
 
The tendency of lipids to form bilayers or vesicles can be rationalized from the 
geometry of these molecules. Generally speaking, the role of molecular geometry in 
dictating the self-assembly of amphiphiles can be understood by a term called the critical 







  (2.2) 
where ahg is the effective area of the amphiphile headgroup and atail is the average area of 
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the amphiphilic tail. Amphiphilic molecules having atail ≈ ahg, i.e., CPP = 1, tend to 
assemble into bilayers or vesicles (Figure 2.2). Note that the shape of these molecules 
resembles that of a cylinder. In contrast, molecules with a larger headgroup area than tail 
tend to favor curved structures, specifically micelles. A CPP of ⅓ corresponds to 
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Figure 2.3. Schematics depicting the connection between the geometry of amphiphilic 
molecules and the structures they form in water. The hydrophilic heads of the 






2.5. Dynamic Light Scattering (DLS) 
DLS probes the Brownian motion of particles in a fluid. This method can give a 
reliable estimate of particle size under certain limiting conditions. In a DLS experiment, 
the fluctuating intensity of light scattered from the sample is recorded at a certain angle θ. 
The fluctuations are then correlated to yield g(2)(q,  ), the intensity autocorrelation 
function, vs. the correlation time  :23 
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                                      (2.3) 
Here q is the scattering or wave vector, and is defined as:  
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where n is the refractive index of the medium. The relevance of q in DLS is that 
structural relaxations are probed over length scales on the order of q–1.  
 
The measured intensity autocorrelation function g(2)(q, ) can be converted into an 
electric field autocorrelation function g(1)(q, ) through the Siegert relation: 
 
2(2) (1)( , ) 1 ( , )g q f g q                                           (2.5) 
Here, f is an adjustable parameter called the coherence factor that depends on the 
instrument geometry. For a dilute solution of monodisperse spherical particles, the 
electric-field autocorrelation function is a single exponential whose time decay is 
determined by the translational diffusion coefficient of the particle D: 
  (1) 2( , ) expg q Dq                                              (2.6) 
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                                                       (2.7) 
where kB is the Boltzmann constant, T the absolute temperature and  the viscosity of the 
solvent (assumed to be a Newtonian liquid). The size obtained from DLS is the 







Liposomes as Theranostic Nanoprobes 
 
The results presented in this chapter have been published in the following journal article: 
Y. Kuo, C. Hung, R. Gullapalli, S. Xu, J. Zhuo, S. R. Raghavan and W. D. D’Souza, 
“Liposomal nanoprobes that combine anti-EGFR antibodies and MRI contrast agents: 
Synthesis and in vitro characterization.” RSC Advances, 4, 33756-33764 (2014)  
 
3.1. Introduction 
The cells of many cancer tumors are known to over-express receptors for growth 
factors on their cell membranes.24-28 An example is the epidermal growth factor receptor 
(EGFR). An abundance of EGFR activates signaling pathways that ultimately leads to 
increased tumor proliferation, migration, and angiogenesis;29 in turn, these cells also 
carry higher risk of metastasis.6,9,30,31 Targeted therapy for some cancers taking advantage 
of the molecular signature of over-expressed EGFR has emerged as a therapeutic option 
in recent years. Simple incubation of anti-EGFR monoclonal antibodies with carcinoma 
cell lines has been shown to inhibit tumor growth and invasion, presumably by blocking 
intracellular EGFR signaling pathways.7,32 This finding has been translated to the clinic: 
specifically, the FDA-approved EGFR-targeting monoclonal antibody Cetuximab 
(Bristol-Myers Squibb, Eli Lilly & Co.) is now used directly as a therapeutic agent 
against head-and-neck and colorectal cancers.9,33 Clinical trials have shown that 
Cetuximab in combination with radiotherapy improved the 5-year overall survival rate of 
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squamous cell carcinoma head and neck (SCCHN) patients to 46%, compared with 36% 
for the radiotherapy-only group.9 When combined with chemotherapy, Cetuximab 
lengthened the median overall survival time from 7.4 to 10.1 months.10   
 
While the protocols for treating cancers with Cetuximab are well-established, 
clinicians currently cannot directly assess the in vivo effectiveness of such targeted agents 
over the course of a multi-week treatment regimen. Computed tomography (CT), positron 
emission tomography (PET), and magnetic resonance imaging (MRI) are the most useful 
live imaging technologies for cancer evaluation.1 Among these methods, MRI is 
advantageous in that it provides high-resolution details and better contrast for 
discriminating between normal and tumor tissue, especially when used in conjunction 
with contrast agents. Contrast agents for MRI fall into two categories: negative-contrast 
(image-darkening) agents like iron oxide and positive-contrast (image-brightening) 
agents, such as gadolinium (Gd). The negative-contrast agents have limitations in 
detecting tumors since the airways surrounding tumors may yield dark signals as well, 
making it difficult to differentiate tumor from air in images. In comparison, positive-
contrast agents like Gd are preferrred. Gd3+ is a strong paramagnetic ion that shortens the 
T1 and T2 relaxation times of nearby water protons, thereby providing an increased signal 
on the MR image.2-4,14 While free Gd3+ ions are quite toxic,34,35 their toxicity can be 
sufficiently lowered by complexing Gd3+ ions with chelating compounds such as 
diethylenetriamine-pentaacetic acid (DTPA).15-17,36-38 The standard clinical injection dose 
of Gd-chelates is about 0.1–0.3 mmol/kg, which results in an average concentration of 
0.5 mM in the extracellular space.16,18 
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To observe EGFR-overexpressing cancer cells via MRI following targeted 
therapy, we have focused on constructing a nanoscale probe bearing both anti-EGFR 
antibodies and a positive MRI contrast agent, i.e., chelated Gd. Such a probe would be 
able to home in on tumor cells due to the antibodies, while the Gd would allow the 
corresponding area to be seen clearly on the MR image. For such a probe to be useful in 
vivo, it would have to be nontoxic and of overall size ~ 100 to 200 nm, which is optimal 
for in vivo circulation and concentration within tumors. Moreover, we wanted to develop 
a probe-synthesis method with as few steps as possible and using commercially available 
ingredients. The rationale was that a simple method would be scalable and allow 
synthesis of the probe in sufficient quantities to be eventually used in the clinic. These 
constraints led us to select liposomes as the optimal choice of nanoscale vehicle. 
Liposomes formed from phospholipids are much less toxic compared to other alternatives 
such as cationic dendrimers.39 Moreover, they can be formed in a single step via self-
assembly, which is a much simpler process than that required typically for polymer-based 
nanoparticles.        
 
We report in this paper the engineering of liposomes that are non-covalently 
conjugated with both Gd-DTPA as well as Cetuximab, the therapeutic anti-EGFR 
antibody. The synthesis strategy is presented in Figure 3.1 and discussed further below. 
The resulting mutlifunctional liposomes are studied in vitro and shown to exhibit 
preferential binding to EGFR-rich SCCHN cells compared to low-EGFR-expressing 
cells. Moreover, we demonstrate the ability to track these structures using MRI. 
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Overall, these liposomes are a promising class of structures for tracking EGFR-
overexpressing cancer cells in real time by MRI.  
 
CAGE Probe


















Figure 3.1. Structure of CAGE probes with Chelated Gd and antibodies to EGFR within 
a single structure of size ~ 100 nm. (Top) The lipids DPPC, Cholesterol, Gd-DTPA-bSA, 
DOPE-mPEG, and DOPE-biotin are combined to produce Gd-liposomes. (Bottom) The 
Gd-liposomes are combined with biotinylated Cetuximab (anti-EGFR antibody) and the 
tetrafunctional protein, avidin. The antibodies get attached to the Gd-liposomes via 
biotin-avidin interactions to form the CAGE probe. “CAGE” includes chelated Gd and 
antibodies to EGFR. 
 
 
3.2. Experimental Section 
Materials. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); 1,2-dioleoyl-sn-
glycero-3-phospho- ethanolamine-N-(biotinyl) (sodium salt) (DOPE-Biotin); DTPA-
bis(stearylamide) (gadolinium salt) (Gd-DTPA-bSA); and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethyleneglycol) -2000] (DOPE-mPEG) were 
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purchased from Avanti Polar Lipids Inc. 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-
indocarbocyanine perchlorate (DiI) was purchased from Molecular Probes. 
Cholesterol, chloroform, and methanol was obtained from Sigma-Aldrich (St. Louis, 
MO). Premixed WST-1 cell proliferation reagent was purchased from Clontech. 
Sulfosuccinimidyl-6-[biotinamido]-6-hexanamidohexanoate (Sulfo-NHS-LC-LC-
Biotin) and the corresponding biotin quantification kit were obtained from Thermo 
Fisher Scientific Inc.  
 
Gd-Liposome Preparation. For Gd-liposome preparation, a lipid mixture consisting 
of DPPC, Cholesterol, Gd-DTPA-bSA, DOPE-mPEG, and DOPE-Biotin (molar ratio 
30:39.9:25:5:0.1) was dissolved in a chloroform:methanol (4:1 v/v) mixture.40 
Fluorescent liposomes were created by including 2 µM DiI. A dried film was formed 
by evaporating the solvent with a dry nitrogen stream, followed by vacuum 
desiccation for 24 h. The dried lipid film was rehydrated with water in 8 mM 
concentration and stirred at 60 °C for 2 h. The mixture was then ultrasonicated at 47.5 
W for 15 min using a probe sonicator (Qsonica, Newtown, CT) to give unilamellar 
liposomes. pH was adjusted to 7.4 using PBS and samples were maintained at 4 °C 
before the experiments. 
 
CAGE Probe Synthesis. 8 mL of 2 mg/mL Cetuximab (anti-EGFR antibody from 
Bristol-Myers Squibb) was purified using Sephadex G-25 column chromatography 
(GE Healthcare). Purified protein was analyzed by measuring OD at 280 nm using a 
NanoDrop 1000 (Thermo Fisher Scientific Inc.). To conjugate cetuxmiab with biotin, 
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the sulfo-NHS-LC-LC-Biotin was mixed with the purified Cetuximab and agitated at 
4 °C for 24 h and purified via Sephadex G-25 column chromatography. The biotin 
quantification kit was used for measuring the biotin per Cetuximab. Finally, the 
biotinylated Cetuximab was combined with Gd-liposomes (at a 1:4 ratio of biotins on 
the antibody compared to the liposomes), and the tetrameric protein, avidin (from 
Sigma-Aldrich) was added at a molar ratio of 1:50  for avidin:total biotin. 
 
Size Measurement. Vesicle size was measured by Dynamic Light Scattering (DLS) 
(Photocor Instruments). A 5 mW laser light source at 633 nm was used to analyze the 
size of vesicles. Studies were done at 25 °C with the scattering angle being 90°. All 
measurements were conducted in triplicate. 
 
Zeta Potential. Surface potentials of vesicles were measured by a Laser Doppler 
Velocimetry technique (Malvern Zetasizer Nano ZS90) at a 90° scattering angle. 
Samples were placed in disposable polystyrene cuvettes (Folded Capillary Cell-
DTS1060, Malvern). All measurements were conducted in triplicate. 
 
Transmission Electron Microscopy (TEM). Samples were characterized by TEM on 
a Jeol JEM 2100 microscope at a 80-kV accelerating voltage. Carbon/formvar coated 
copper grids (Ted Pella, Inc.) were dipped into the solution containing the vesicle 
samples and then placed in a fume hood for 5 min. The dried TEM grids were then 
stained with a drop of 1% uranyl acetate (from Sigma-Aldrich) solution and the 




MR Properties of the Liposomes. For T1-weighted MR imaging, the samples (Gd-
liposome/CAGE probe) were transferred to a 2 mL Eppendorff tube. Inversion 
recovery pulse sequence was used for the measurement of T1 relaxation time by the 
least-squares algorithm using a 3.0 Tesla Siemens MAGNETOM-Trio system at 25 
°C with the following settings: echo time (TE) = 12 ms, repetition time (TR) = 6000 
ms. Thirteen different inversion-recovery waiting delay values (TI) between 40 ms 
and 2800 ms were measured (slice thickness = 5 mm). The signal intensity of each 
tube in the MRI was measured by placing a region of interest in the center of the 
cross-sectional images of the tube under different TI. T1 values of each tube were 
calculated by fitting the collected data to the following function: f(x) = m(1 – 2exp(–
TI/T1)) using Matlab, where f(x) is the corresponding signal intensity and the fitting 
parameters are m and T1. A plot of 1/T1 versus Gd3+ concentration yielded a straight 
line with the slope being the samples’ T1 relaxivity value r1.  
 
Cell Lines. SCCHN 15B cells were provided by Dr. Jennifer Grandis (University of 
Pittsburgh) and HEK293 human embryonic kidney cells were purchased from 
American Type Culture Collection. Cells were cultured in DMEM medium for 
HEK293 (Invitrogen) or RPMI-1640 medium for 15B with 10% FBS (Hyclone), 1% 
L-glutamine (Sigma-Aldrich) and maintained at 37 °C and 5% CO2. Cells were 
propagated to 80% confluency prior to the in vitro assay. Phosphate buffered saline 




Flow-Cytometry Analysis of EGFR Expression. HEK and 15B were incubated at 37 
°C for 1 h with Alexa Fluor labeled anti-EGFR antibody, sc-120 AF488 (green 
fluorescence, purchased from Santa Cruz Biotechnology, CA) at dilutions of 1/1000 
and 1/3000 with PBS. Excess antibody was removed from the cells by washing three 
times with PBS and 5  105 cells were collected in 500 µl PBS. EGFR expression for 
each cell line were analyzed by counting cells emitting green fluorescence by a 
FACScan (Becton-Dickinson). Additionally, Alexa Fluor signals in the cells were 
directly visualized by fluorescence microscope (Olympus BX60). 
  
Cell Viability. Cells were plated in 96-well plates at a density of 104 cells per well 
containing 100 µL of culture medium; after 24 h of cultivation, the cells were 
incubated with varying concentrations of vesicles. After 24 h of incubation, cell 
viability was evaluated by MTT assay using Premix WST-1 cell proliferation reagent 
(Clontech), and measuring the absorbance at 440 nm by a SpectraMax M2 
spectrometer (Molecular Devices). All experiments were performed in triplicate. 
 
Cell Targeting and Competition Assays. 104 cells were seeded onto an 8-well 
chamber slide. After overnight culture, cells were blocked with a culture medium 
containing 1% BSA at 37 °C for 30 min, and the CAGE probe or Gd-liposome was 
added at 2 mg/mL for 2 h of incubation at 37 °C. After washing with PBS three times, 
the samples were fixed with 2% paraformaldehyde, and slides were mounted with 
antifade, 4′,6′-diamidino-2-phenylindole (DAPI)-containing fluorescent mounting 
media (EMD Chemicals), and visualized under a fluorescence microscope. For the 
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competition assay, 15B cells were incubated with 1:50 sc-120 AF488 antiEGFR 
antibody at 37 °C for 40 min, washed with PBS, and then incubated with different 
concentrations of CAGE probe for 1 h in a 37 °C incubator. After the same fixation 
steps above, slides were prepared and stored at 4 °C. The fluorescence intensity 
evaluation was done by ImageJ software (NIH). After manually selecting the region 
containing cells, total fluorescence intensity was acquired. To get the average 
fluorescence intensity per cell, the total intensity was divided by the number of cells. 
The result is the specific fluorescence intensity, which represents the average 
intensity of each cell. 
 
Liposome Targeting Assay by MRI. 15B cells were cultured in several T175 flasks. 
In one flask, 12 mL of CAGE probe in cell medium (corresponding to 6 mM Gd3+) 
was added. In another flask, 12 mL of Gd-liposomes in cell medium (also 
corresponding to 6 mM Gd3+) along with free Cetuximab (equal to that in the flask 
with the CAGE probe) was added. Each flask was incubated for 1 h at 37 °C. The 
same process was repeated with additional cell-bearing flasks. Thereafter, all the cells 
were collected by centrifugation and washed three times with PBS. The cells were 
then fixed with 4% paraformaldehyde for 20 min at 4 °C. Then, the cells were placed 
in Eppendorff tubes for MR screening. The MR protocol is the same as described 
above to evaluate the Gd concentration bound to cells. 
 
3.3. Results and Discussion 
Preparation of Multifunctional Liposomal Nanoprobes 
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The base liposomal formulation employed here is a mixture of the 
phospholipid DPPC and cholesterol. We sought to conjugate both Gd-DTPA and 
antibodies to such liposomes. Towards this end, three additional lipids were 
introduced into the formulation, as shown in Figure 3.1. The first lipid, Gd-
DTPA-bSA, has Gd-DTPA bound to two stearyl tails by amide linkages. The second 
lipid, DOPE-biotin, has two oleyl tails and a biotin attached to the lipid headgroup. A 
third lipid, DOPE-PEG was also added to the formulation; this lipid has two oleyl 
tails and a polyethylene glycol (PEG) oligomer (2000 Da) attached to the headgroup.  
The five molecules, i.e., DPPC, cholesterol, Gd-DTPA-bSA, DOPE-PEG, and DOPE-
biotin were combined at a molar ratio of 30:39.9:25:5:0.1 for a typical formulation, 
with the overall lipid concentration being 6 mg/mL or 8 mM. Liposomes were 
prepared by sonication and we refer to the overall structures as Gd-liposomes. Note 
that the DOPE-PEG provides PEG chains on the exterior of the liposome, which 
impart steric stability and are expected to enhance the in vivo circulation time.41 
 
The size and stability of Gd-liposomes were evaluated using dynamic light 
scattering (DLS). Liposome diameters for the typical composition noted above were 
measured to be 100 nm, 120 nm, respectively (Figure 3.2) and the sizes remained 
unchanged over three weeks of observation. The proportion of the Gd-DTPA-bSA 
lipid had an impact on liposomal stability. Since a higher fraction of Gd-DTPA-bSA 
in the liposomal bilayer would yield an increased signal in MRI, we attempted to 
increase this fraction (while reducing the cholesterol fraction). However, if the Gd-
DTPA-bSA fraction was raised above 25 mol%, the liposomal diameter increased 
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substantially over time (data not shown), and in some cases, precipitation was 
observed. These observations indicate aggregation or destabilization of the liposomes. 





























Figure 3.2. Liposome size and stability over a period of 18 days. Data are shown for Gd-
liposomes (no antibody) and for the CAGE probes (liposomes with antibody attached). 
The sizes correspond to the hydrodynamic diameters from DLS. 
 
The above Gd-liposomes had a zeta potential of +5.13 mV in water, indicating 
a net cationic nature. Among the lipids used, DPPC is zwitterionic and cholesterol is 
nonionic. The PE headgroups in DOPE-PEG and DOPE-biotin are anionic, but the 
fractions of these lipids in the formulation is low (5 and 0.1 mol%, respectively). 
Thus, the cationic nature of the overall liposomes is evidently arising from the Gd-
DTPA-bSA lipid, and more specifically from the Gd3+. The weak positive charge on 
the liposomes may be beneficial as it can provide electrostatic repulsions between 
them, which helps to stabilize the liposomes. The Gd-liposomes were also studied in 
PBS buffer and were again found to be stable over time. However, measurements of 
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the zeta potential in buffer did not yield consistent values, possibly because of the 
screening of electrostatic interactions by the ions in PBS. Thus, stability in PBS may 
be attributed primarily to steric repulsions from the PEG side chains. TEM images of 
Gd-liposomes negatively stained by uranyl acetate (Figures 3.3a, 3.3b) show that 
these liposomes are unilamellar spheres with diameters around 100 nm, which is 
broadly consistent with the DLS data above.         
 
We then proceeded to attach antibodies to the Gd-liposomes. The antibody 
chosen was Cetuximab, the therapeutic anti-EGFR antibody, and we first chemically 
affixed biotins to it by the reaction shown in Figure 3.1. Each Cetuximab acquired ~3 
biotins by this reaction. The biotinylated Cetuximab was then combined with the 
Gd-liposomes (bearing DOPE-biotin) in the presence of avidin, a tetrameric biotin-
binding protein. A molar ratio of overall biotin:avidin = 50:1 was used and the ratio 
of biotins on Gd-liposomes versus biotins on Cetuximab was kept at 1:4. The 
components were mixed by agitation for 40 min and then maintained at 4 °C. In the 
process, Cetuximab becomes bound to the liposomes, as shown in Figure 3.1. We use 
the term “CAGE” to refer to the final liposomal structures since they combine 
chelated Gd as well as antibodies to EGFR. The CAGE probes were characterized by 
DLS (Figure 3.2) and TEM (Figure 3.3c, 3.3d). Figure 3.2 shows that the CAGE 
probes were also around 100 nm in diameter. They were slightly larger than the Gd-
liposomes. This finding is consistent with antibody conjugation. TEM also reveals 
that the CAGE probes are unilamellar liposomes with sizes consistent with those 




Figure 3.3. TEM images of liposome structures stained with 1% uranyl acetate. (a,b) Gd-
liposomes; (c,d) CAGE probes. 
 
Quantification of MR Contrast 
Next, we quantified the MR signal of the above structures using a 3 T scanner. 
These studies were done with the Gd-liposomes and the CAGE probe. Gd-DTPA 
solutions were used as the standard for comparison. The longitudinal relaxation times 
T1 for Gd-liposomes, the CAGE probe and Gd-DTPA solutions were measured at 
various dilutions. Plots of 1/T1 versus [Gd3+] for all sets of samples follow straight 
lines (Figure 3.4). The inverse relationship confirms that the higher the [Gd3+], the 
shorter the relaxation time T1. The slopes of the lines are defined as the relaxivities r1 
for each class of samples. r1 was 3.3 mM-1s-1 for Gd-DTPA solutions, 8.07 mM-1s-1 
for the Gd-liposomes and 3.93 mM-1s-1 for the CAGE probe. The r1 values of Gd-
liposomes and CAGE probes were 2.4 and 1.19 times higher than that of Gd-DTPA, 
respectively. This implies that the Gd-bearing nanostructures give rise to greater MR 
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contrast than Gd-DTPA. The r1 enhancement for the Gd-liposomes may be the result 
of their being embedded in bilayers,42 which restricts the internal (rotational) motion 
of Gd. Higher relaxivity due to restricted internal motion of Gd has been reported 
previously.43,44 The CAGE probe may have decreased r1 compared with Gd-liposomes 
because the linkage of avidin and the biotinylated antibody may shield the Gd in the 
liposomal bilayer from interactions with water, which would decrease the density of 
Gd-coordinated water molecules. It is worth noting that the T1 time for water is 2383 
ms and it is 2252 ms for the bare liposomes without Gd (negligible difference). In 
comparison, the inclusion of the Gd-DTPA-bSA lipid in the liposomes at a 
concentration of 2.0 mM reduces the T1 time to 61 ms. This difference between bare 
and Gd-liposomes (2252 ms to 61 ms) is large enough to give appreciable contrast in 
MR images.    
[Gd3+] / (mM)





















Figure 3.4. Relaxivity plots of 1/T1 vs. Gd3+ from MR measurements. Plots are shown for 
solutions of Gd-DTPA as well as for solutions containing Gd-liposomes. The slopes of 
the lines give the relaxivities for each sample (Gd-liposomes: r1 = 8.07 mM-1s-1, CAGE 





Figure 3.5. EGFR expression of normal HEK cells compared with that of SCCHN 15B 
cells by flow cytometry and fluorescence microscopy. (a) Very low Alexa Fluor 
fluorescence signal (green) is observed with HEK cells (2.79%) which implies low levels 
of EGFR expression. (b) In comparison, a high Alexa Fluor signal is found for 15B cells 
(99.8%). Note that in the micrographs, the cell nucleus stained by DAPI gives blue 
fluorescence, while the Alexa Fluor-bound antibody gives green fluorescence. 
 
 
EGFR Expression: SCCHN vs. Normal Cells 
As noted in the Introduction, most SCCHN cell lines are known to over-
express EGFR, and one such cell line is the 15B line.45,46 We used SCCHN 15B as the 
positive control in targeting assays with our CAGE probes. For comparison, a human 
embryonic kidney cell line (HEK 293) was used to represent normal cells with low 
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EGFR expression. To confirm that SCCHN 15B cells exhibited higher EGFR 
expression levels compared to HEK 293 cells, each type of cells was contacted with 
an anti-EGFR antibody (sc-120 AF488) conjugated with the green fluorescent moiety, 
Alexa Fluor. Thereafter Alexa Fluor-positive cells were analyzed by flow cytometry 
and fluorescence microscopy. As expected,47,48 HEK 293 cells exhibited very low 
levels of EGFR expression with only 2.8% Alexa Fluor-positive cells detected by 
flow cytometry and almost no Alexa Fluor signal (green) in the fluorescence 
micrograph (Figure 3.5a). On the other hand, SCCHN 15B cells exhibited high 
expression levels of EGFR with nearly 100% of cells detected as Alexa Fluor-positive 
in flow cytometry (Figure 3.5b). These results confirmed the distinctive expression 
levels of EGFR between 15B and HEK 293 cells.  
 
Cytotoxicity of CAGE probe on SCCHN 15B Cells 
Before proceeding to the targeting assay, the cytotoxicity of the Gd-liposomes 
and the CAGE probes was investigated. SCCHN 15B cells were incubated with 
different concentrations of Gd-liposomes or CAGE probes for 24 h and the fraction of 
surviving viable cells was determined by the MTT assay. The data are presented in 
Figure 3.6. In the case of Gd-liposomes, more than 80% of cells remained viable at 
liposome concentrations between 0.01 to 1 mg/mL, while 50% of cells survived at 5 
mg/mL. The assay thereby validates that the Gd-liposomes as relatively nontoxic, and 
this finding has also been confirmed by other researchers for similar liposomes.49,50 
Compared with Gd-liposomes, the CAGE probes showed some toxicicty to cells: 70% 
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of cells remained viable at a probe concentration of 1 mg/mL while 20% of cells 
survived at a concentration of 3 mg/mL. 
 



























Figure 3.6. Cell viability (MTT) assay of 15B cells incubated with different structures. 
Gd-liposomes show low toxicity to cells, while the CAGE probes are somewhat toxic 
above 2 mg/mL. 
 
Targeting Ability of CAGE Probes  
To evaluate the targeting ability of CAGE probes, we chose a concentration of 
2 mg/mL. The procedure for the experiment was based on that used by Mulder et al.51 
and was designed to test whether the CAGE probes could specifically target EGFR-
over-expressing cells. Gd-liposomes (no conjugated antibody) were used as the 
control. To assess targeting by fluorescence microscopy, an additional fluorescent 
lipid probe (DiI) was added to the liposomal bilayers of both the CAGE and the Gd-
liposomes. We used live HEK 293 and SCCHN 15B cells for the targeting 
experiments. The experiments involved incubating the cells with the probes (or the 
controls) for 2 h, followed by washing to remove unbound probes, and then imaging 
of the cells for fluorescence from DiI. Although the probes were somewhat toxic at 
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this concentration over the 24 h time period in the MTT assay (Figure 3.6), they are 
not expected to significantly affect the cells over the shorter incubation time of 2 h in 
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Figure 3.7. EGFR-mediated binding of Gd-liposomes and CAGE probes by HEK and 
15B cells. Since the Gd-liposomes do not have any targeting function, they show some 
non-specific binding to both HEK cells (a) and 15B cells (b). On the other hand, the 
CAGE probes are able to bind significantly more to EGFR-overexpressing 15B cells (d) 
compared to HEK cells (c). 
 
The results of the targeting experiments are shown by the fluorescence 
micrographs in Figure 3.7. The red color in the images indicates fluorescence from 
DiI in the liposomal membranes. As expected, the Gd-liposomes gave a similar weak 
red signal for both the SCCHN and normal cell lines, indicating that these liposomes 
randomly bind to cells without specificity (Figures 3.7a and 3.7b). On the other hand, 
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in the case of the CAGE probes, a significantly higher signal was observed with the 
EGFR-over-expressing SCCHN 15B cells compared to the normal HEK 293 cells 
(Figures 3.7c and 3.7d). These results indicate cell specificity and membrane binding 
of the CAGE probe against the 15B cells. The differences in fluorescence signals 
were quantified using Image J software. For the CAGE probes combined with 15B 
cells, the specific fluorescence intensity (per cell) was 41 ± 7. In comparison, for the 
CAGE probes with HEK 293 cells, the intensity (per cell) was 12 ± 6. Lastly, for the 
Gd-liposomes together with 15B cells, the intensity (per cell) was 14 ± 6. Thus, there 
is a 3-fold higher fluorescence per cell in the case of the CAGE probe incubated with 
15B cells, relative to the two controls. This higher signal is evidently a result of 
binding of the CAGE probe to EGFR receptors on the 15B cells.  
 
Competitive Targeting of CAGE vs. anti-EGFR Antibody 
To further evaluate the targeting ability of CAGE probes, we conducted a 
competition assay using the CAGEs against the anti-EGFR antibody (sc-120 AF488) 
(used also for EGFR quantification by flow cytometry). First, SCCHN 15B cells were 
incubated with the sc-120 antibody, which resulted in a strong green signal due to 
Alexa Fluor (green fluorescence) around the cells (Figure 3.8a). The same cells were 
contacted with a low concentration (0.1 mg/mL) of CAGE for 1 h, whereupon, the 
Alexa Fluor signal decreased and a dim red signal due to DiI in the CAGE was barely 
visible (Figure 3.8b). When the CAGE probes were added at medium concentration 
(0.8 mg/mL), the Alexa Fluor signal decreased further and a clear red signal from the 
CAGE became visible (Figure 3.8c). Finally, when a high concentration of CAGE (2 
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mg/mL) was introduced, the Alexa Fluor signal was nearly eliminated and all cells 
showed a distinctive red envelope, showing the binding of CAGE probes (Figure 
3.8d). These results clearly show that the affinity of CAGE probes for EGFR on 15B 
cell membranes is comparable to that of the sc-120 antibody.  
 
 
Figure 3.8. Competition assay of CAGE probes (red) with the sc-120 AF488 EGFR 
antibody (green) for evaluation of specific binding affinity in 15B cells. (a) 1:50 sc-120 
alone (b) 1:50 sc-120, 0.1 mg/mL of CAGE, (c) 1:50 sc-120, 0.8 mg/mL of CAGE, (d) 
1:50 sc-120, 2 mg/mL of CAGE. 
 
In Vitro Study of CAGE-Targeted 15B Cells using MRI 
Finally, we used MRI to screen a sample of 15B cells with bound CAGE 
probes. For this experiment, 15B cells were combined with CAGE probes at a 
concentration of 5 mg/mL (0.5 mM Gd) and incubated for 1 h. The cells were then 
washed with buffer to remove unbound CAGE, fixed and placed in an Eppendorf tube 
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for MRI scanning. For comparison, we also scanned tubes containing water and a 
0.5 mM solution of Gd-DTPA. The corresponding cross-sectional images are shown 
in Figure 3.9; these images correspond to an inversion time, TI = 1000 ms. From 
images corresponding to various inversion times, the T1 relaxation times were 
calculated. The water sample has a T1 of 2252 ms, consistent with the relatively dark 
image. The 0.5 mM Gd-DTPA solution, in comparison, has a much lower T1 of 381.4 
ms, which reflects the much brigher image. The conjugate of Gd-liposome (which 
serves as a control with 0.5 mM Gd) incubated with 15B cells, resulted in a T1 of 
516.2 ms, which is 1.5 times higher than the Gd-DTPA solution. Finally, the 15B 
cells with bound CAGE probe yielded a T1 of 379.3 ms, which is similar to the T1 of 
0.5 mM Gd-DTPA. The level of contrast in this image is more than sufficient for 
imaging purposes. Thus, we conclude that our Gd-bearing CAGE probes are capable 
of providing MRI images with sufficient resolution if the probes can effectively bind 
to their targets. Future studies will examine these probes in vivo using animal models 
of SCCHN.      
 
 
Figure 3.9. MRI screening of CAGE probe-targeted 15B cells. T1 values and MR images 
at TI =1000 ms for pure water, 0.5 mM Gd-DTPA, Gd-liposome and CAGE probe-
targeted 15B cells. T1 values were calculated based on the intensity inside the circle by 





In this study, we have developed CAGE probes as a class of biocompatible 
nanostructures capable of binding selectively to cells that have an over-abundance of 
EGFRs on their membranes. Simultaneously, the CAGE probes are decorated with 
Gd-DTPA-bearing lipids, which enables them to provide positive contrast in MR 
images to regions with high levels of probe binding. In preparing these probes, we 
have deliberately chosen a simple, two-step procedure that uses materials that are 
commercially available, biologically-derived, biocompatible and non-toxic. The 
procedure involves self-assembly of a mixture of five lipids: DPPC, cholesterol, a 
lipid with Gd-DTPA, a PEGylated lipid, and a biotinylated lipid to yield liposomes of 
~ 100 nm diameter. Thereafter, in a second self-assembly step, the above liposomes 
are combined with biotinylated cetuximab (commercial anti-EGFR antibody) in the 
presence of the linker protein avidin. The resulting CAGE probes are stable in 
solution and show minimal toxicity to cells. Using fluorescence-based in vitro assays, 
we have confirmed that the probes bind preferentially to EGFR+ cells compared to 
EGFR– cells. The MR relaxivity of these probes is sufficient to provide reasonable levels 
of positive contrast in MR images. In future studies, we will examine the binding of 
CAGE probes in vivo using animal models of SCCHN. The eventual goal is to use these 
probes to track the uptake of targeted agents in patients during the course of a typical 7-
week cancer treatment. It is hoped that the tracking ability using MRI will eventually 
enable physicians to personalize the treatment for each patient and thereby help to 





Micro-Erythrosomes and Their Colloidal Properties 
  
4.1. Introduction 
In Chapter 3, we had investigated the use of liposomes as theranostic structures. 
As is well-known (see Chapter 2), the structure of liposomes mimics the structure of a 
typical biological cell, i.e., both liposomes and cells have a lipid membrane enclosing 
internal contents.52,53 Given this analogy, one can turn back to biological cells and ask if 
it is possible to empty the contents of the cells and thereby obtain the equivalent of 
liposomes. In this context, erythrocytes, i.e., red blood cells (RBCs), from animal or 
human sources are an attractive candidate. They are responsible for transporting oxygen 
from the lungs to the tissues and exchanging carbon dioxide from the tissues to the lungs 
for expiration. RBCs have a life span of 120 days in the human body, which greatly 
exceeds the lifetime of any synthetic drug carrier that has been developed so far.54 Also, 
RBCs have no nucleus or organelles and also do not contain nucleic acid matter; they are 
essentially containers filled with hemoglobin and therefore are relatively easy to empty.  
 
The idea of using erythrocytes as carriers for a substance other than (or in addition 
to) hemoglobin dates back to the 1970s.55 Empty erythrocytes were created by osmotic 
shock, centrifugation, and repeated washing. These are termed “erythrosomes” or 
“ghosts”; here, we will refer to them as micro-erythrosomes (MERs) (to distinguish from 
the smaller nano-erythrosomes that we will discuss in Chapter 5. MERs tend to be about 
the same size as the original RBCs (i.e., around 4 µm in diameter). Several methods have 
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been reported to encapsulate drugs or other chemicals in MERs, such as electrical pulse 
methods,56 hypo-osmotic methods,57-59 and hydrophobic insertion into the membrane.60,61 
However, there is still only a limited number of studies on these structures, especially 
from the viewpoint of colloid science.  
 
In this study, we have isolated MERs from bovine blood and explored their use in 
the targeted delivery of solutes. We have studied the ability of MERs to encapsulate 
solutes such as the MRI contrast agent Gd-DTPA in their core. We have also attempted to 
decorate the MER membranes with targeting agents such as anti-EGFR antibodies. Our 
studies show that MERs have several interesting properties that may make them suitable 
for delivery applications.    
 
4.2. Experimental Section 
Materials. Bovine blood was purchased from Lampire Biological Laboratories. 1,2-
dioleoyl-sn-glycero-3-phospho- ethanolamine-N-(biotinyl) (sodium salt) (DOPE-Biotin) 
was purchased from Avanti Polar Lipids. Dextran-FITC were obtained from Sigma-
Aldrich. 1,1'-dioctadecyl- 3,3,3',3'-tetramethyl-indocarbocyanine perchlorate (DiI) and 
3,3’-Dioctadecyl-oxacarbo-cyanine perchlorate (DiO) were purchased from Molecular 
Probes. Phosphate buffered saline (PBS); Fetal bovine serum (FBS); Streptavidin 





Microerythrosomes Preparation. The microerythrosomes were prepared from whole 
blood by centrifugation as previously described in Chapter 4.62 Briefly, red blood cells 
(RBCs) were first separated from 100 mL whole blood by centrifugation (3 times at 2000 
rpm, 10 min). RBCs were washed with cold PBS (pH 7.4). Then the RBCs was 
resuspended in hypotonic PBS (pH 7.4) which contained 0.14 M NaCl, 0.01 M 
phosphate, 0.003 M KCl and incubated for 5 min on ice. The solution was transferred to a 
Beckman SW28 ultracentrifuge and spun at 12,000 rpm for 10 min at 4°C. Subsequently, 
the pellet was resuspended in cold PBS to give the MERs. pH was kept at pH 7.4 using 
PBS and samples were maintained at 4°C before the experiments. Fluorescent MERs 
were created by including 2 µM DiI in ethanol, while biotinylated MERs were made by 
including DOPE-biotin. MERs with antibodies were created as follows: biotinylated 
Cetuximab (anti-EGFR antibody from Bristol-Myers Squibb) was combined with 
biotinylated MERs (at a 1:5 ratio of biotins on the antibody compared to the MERs), and 
the tetrameric protein, avidin (from Sigma-Aldrich) was added at a molar ratio of 1 : 60 
for avidin : total biotin, followed by a PBS wash. 
 
Size Measurement. MER sizes were extracted from optical microscope images via the 
ImageJ software (NIH). Sizes were averaged over 150 structures in an image All 
calculations were conducted in triplicate. 
 
Zeta Potential. Surface potentials of ERs were measured by a Laser Doppler 
Velocimetry technique (Malvern Zetasizer Nano ZS90) at a 90° scattering angle. Samples 
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were placed in disposable polystyrene cuvettes (Folded Capillary Cell-DTS1060, 
Malvern, UK). All measurements were conducted in triplicate. 
 
Encapsulation in Microerythrosomes. MERs were prepared by the method above and 
incubated with FITC-Dextran in 0.1x PBS for 1 h at 4°C.58 A sealed sample was then 
added to 10x PBS (isotonic conditions) and placed in a water bath at 37°C for various 
times. The samples were observed by the Zeiss LSM710 microscope and the fluorescence 
intensity was measured by the plate reader (Ex: 492 nm, Em: 518 nm).  
 
Cell Targeting Assay of Microerythrosomes. 104 15B cells were seeded onto an 8-well 
chamber slide. After overnight culture, cells were blocked with a culture medium 
containing 1% BSA at 37°C for 30 min, and the MERs prepared as described above were 
added for 1 h of incubation at 37°C. After washing with PBS three times, the samples 
were fixed with 2% paraformaldehyde, and the slides were mounted with antifade, 4′,6′-
diamidino-2-phenylindole (DAPI)-containing fluorescent mounting media (EMD 





4.3. Results and Discussion 





















Figure 4.1. Preparation of MERs from bovine whole blood. Red cells were separated, 
burst via hypotonic PBS to cause hemoglobin release, and purified via ultracentrifugation 
to remove the hemoglobin in the supernatant. Unlysed MERs are in the bottom pellet. 
The MERs were then functionalized with antibody using biotin-avidin linkages. 
 
The procedure for preparing MERs is shown in Figure 4.1. We use bovine blood, 
which has a hematocrit, i.e., volume fraction of RBCs, of about 20% (in human blood, 
the hematocrit is about 40%). In terms of number density, we measured the concentration 
(by a cytometer) of cells in the blood to be about 3  109 cells/mL. RBCs were separated 
from the white cells, platelets, and serum by centrifugation, i.e., by exploiting differences 
in density between the different components. The separated RBCs were then placed in 
hypotonic PBS. This induced the hemoglobin in the cells to be leached out due to the 
osmotic gradient between the cells and the solution. The process was carried out over a 
couple of cycles, and at the end, the pellet at the bottom of the centrifuge tube contains 
the cells without hemoglobin, which have a characteristic pink or white color. These are 
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the microerythrosomes (MERs), and they can be resuspended as a stable dispersion either 
in deionized (DI) water or in PBS. The concentration of MERs measured by the 
cytometer was 1 to 1.5  109 /mL, i.e., the yield was between 30 to 50%.  
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Figure 4.2. Stability of microerythrosomes. a) MERs in PBS over a period of two weeks. 
b) Zetapotential of MERs is about -30 ~ -40 mV. 
 
Characteristics of MERs 
The size and stability of MERs were evaluated using optical microscopy. The 
MERs in isotonic PBS ranged from 2 to 6 μm in diameter, and the mean was ~ 4 μm. The 
same size was maintained over 18 days of observation (Figure 4.2a). The shape of the 
MERs was similar to the original RBCs, i.e., both were biconcave discs in isotonic 
solution. However, in hypotonic solutions, their shape changes to an isotropic sphere. The 
surface charge of the MERs was measured, and their zeta potential was found to be 
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between –30 and –40 mV (Figure 4.2b). These measurements confirm that the MERs 
have a net negative charge, which helps in stabilizing these structures against aggregation. 
The negative charge is likely to come from anionic lipids such as phosphatidylserine (PS) 
in the MER membranes.63 Overall, our results suggest that the MERs are identical to the 
RBCs in terms of their size, shape, and membrane properties, with the only difference 
being that the core of the MERs is empty whereas the RBCs contain hemoglobin.  
 
Functionalization of MERs 
The membranes of MERs can be tagged with other lipids quite easily. For 
example, the red fluorescent lipid DiI was incorporated into MERs as follows. A sample 
of DiI in ethanol was mixed with a suspension of MERs in PBS. The mixture was then 
centrifuged and the pellet was resuspended in water. When observed under fluorescence 
microscopy, we found a number of red spherical shell-like structures in this sample, 
indicating incorporation of DiI into the MER membranes. A similar procedure was 
repeated with the green fluorescent lipid DiO, thus forming MERs with green-fluorescent 
membranes. Next, we combined the DiI-coated MERs and the DiO-coated MERs into the 
same sample in a 1:1 ratio by weight. Figure 4.3 is a micrograph of this sample 
overlaying the green and red fluorescence. We note the co-existence of green and red-
stained spherical shells in this figure. The structures are swollen because they are in water 
(hypotonic environment), which is why they appear as spheres rather than discs. 
Interestingly, there was no crossover of lipid from one membrane to another, i.e., the 
fluorescence of each population of MERs was retained over time. This shows that the 
MER membranes are intact. Note that the crossover of lipids across water from one 
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Figure 4.3. Decoration of MERs with fluorescent lipids. The figure is a superimposition 
of green and red fluorescence from a sample containing a 1:1 mixture of MERs with the 
red fluorescent lipid DiI and MERs with the green fluorescent lipid DiO. The structures 
are suspended in water (hypotonic solution), and hence are swollen into spheres. 
 
Overall, the experiment above shows that MERs can be manipulated as colloidal 
entities, much like giant vesicles. In this regard, MERs are different from their parent 
RBCs. To show this, we mixed a sample of DiI in ethanol with a suspension of RBCs in 
PBS. This mixture was centrifuged and the pellet was resuspended in water or buffer. 
Examination by fluorescence microscopy showed that very few of the RBCs were stained 
red by the DiI; most of the RBCs showed no fluorescence at all. Thus, when the RBCs 
are intact, they do not readily permit foreign lipids to be incorporated into their 








Figure 4.4. Surface modification of MERs by biotin-avidin interactions. (a) MERs with 
DiI and DOPE-Biotin show red fluorescence. (b) To this, when avidin-FITC is added, we 
see green fluorescence at the same spots, indicating binding of avidin to the biotins on the 
MERs. (c) A superimposed image of green and red fluorescence confirms this binding. 
 
Next, we used biotin-avidin interactions to functionalize the MERs. First, we 
tagged the MERs with two lipids: DiI and DOPE-biotin and suspended these in PBS. The 
resulting structures should show red fluorescence due to the DiI. Then, we combined 
these MERs with the protein avidin, which itself has been tagged with the green 
fluorescent molecule FITC. The mixture was then subjected to washing steps to remove 
unbound avidin-FITC. When this sample is imaged by fluorescence microscopy, we see 
structures that simultaneously show red fluorescence due to the DiI (Figure 4.4a), as well 
as green fluorescence due to the FITC (Figure 4.4b). The combined image confirms that 
the two kinds of fluorescence overlap with each other. In turn, this indicates that the 
avidin-FITC binds to the biotins on the MER membranes by strong non-covalent 
interactions. Note that this route for MER surface modification is very straightforward 
because it involves self-assembly rather than chemical reactions. Traditional surface 
modification of nanoparticles is done using chemical reactions, i.e., the formation of 
covalent bonds such as between NHS and carboxyl groups, maleimide and thiol groups, 
or aldehyde and amine groups.2,62,64 Chemical routes are usually more difficult and 
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complex because the synthesis schemes do not always go to completion, and moreover, 





Figure 4.5. Imparting magnetic properties to MERs. This is done by binding streptavidin-
coated magnetic beads to MERs with DiI and biotin. The images are stills from a movie, 
in order from a to d. The arrows indicate the motion of MERs at different time points. 
 
Another use of biotin-avidin interactions is demonstrated in Figure 4.5. Here, we 
start with MERs decorated with DiI and DOPE-biotin and we incubate these with  
streptavidin-conjugated magnetic beads (1 µm in diameter). The mixture is then observed 
under a fluorescent microscope. The MERs show red fluorescence due to the DiI. The 
magnetic beads cannot be seen, but are bound to the MERs due to biotin-avidin 
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interactions. When an external magnet is rotated or swayed, the MERs move along with 
the magnet, as shown by Figure 4.5a-d, which are still images from a movie. Note that 
some MERs, which are clearly disc-like, change their orientation under the magnet, i.e., 
the disc is seen edgewise in Figure 4.5a whereas the disc is flat in Figure 4.5b. Overall, 
we are able to impart magnetic properties to the MERs by exploiting biotin-avidin 
interactions.    
 
Solute Encapsulation and Release from MERs 
Next, we evaluate the encapsulation capability of MERs within their aqueous 
cores. For this, dextran-FITC (molecular weight ~ 4,000 Da) was chosen as the solute. To 
encapsulate the solute in the MERs, we first added the solute to the MER suspension at 
room temperature under hypotonic conditions. During this time, the MER membrane gets 
ruptured and some of the solute gets internalized. We then altered the conditions so as to 
facilitate resealing of the membrane. This involves increasing the osmolarity of the 
solution to 1X PBS, warming to 37°C, and holding at that temperature for some period of 
time (typically 1 h). Following this “resealing procedure”, the sample is centrifuged and 
the pellet is resuspended in isotonic PBS.  
 
The importance of the resealing procedure for solute encapsulation is shown by 
Figure 4.6. First, as a comparison, we show data for the RBCs, which still contain 
hemoglobin. In this case, we add the solute, follow the resealing procedure, and then 
resuspend the RBCs in PBS. A small extent of fluorescence is seen in Figure 4.6b, 
indicating that only a little of the dextran-FITC gets into the RBC core. Next, we consider 
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the MERs, with the solute encapsulated, but no resealing done. In this case, the unsealed 
MERs do not show any fluorescence at all (Figure 4.6d). Finally, the sealed MERs are 
shown in Figure 4.6f, and in this case, substantial fluorescence is seen, indicating that an 
appreciable amount of dextran-FITC is present in the cores of the MERs. Note that the 
the RBCs show higher contrast in the bright field image than the MERs because of the 
hemoglobin in them. The sealed MERs are slightly smaller than the RBCs, but their 
fluorescence signal is much higher. The different fluorescence intensities from the above 
samples were also quantified using a plate reader. Relative to the unsealed MERs (= 1), 
the intensities for RBCs and sealed ERs were 6.5 and 26, respectively. These values are 
consistent with the microscopy results. They indicate that sealed ERs can accommodate 4 















Figure 4.6. Encapsulation of dextran-FITC in various structures. The images on the left 
are bright field views while those on the right are for green fluorescence. (a) and (b) 
sealed RBCs; (c) and (d) unsealed ERs; (e) and (f) sealed ERs. 
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The above data indicate that MERs must be sealed for effective encapsulation of 
cargo. Since the sealing process is critical, we investigated the variables involved, 
including sealing time and sealing temperature. The control sealing conditions employed 
earlier were to hold the sample at 37°C for 1 h in 1X PBS. Results were compared in 
terms of the fluorescence intensity I from the plate reader, with I normalized to a value of 
1 for a sealing time of 0 min. Our data show that longer sealing times give higher 
encapsulation. Sealing times of 5 min, 40 min, and 60 min gave I = 7, 14 and 16, 
respectively. Thus, a minimum sealing time of 40 min is recommended. The sealing 
temperature was not found to be a significant factor. If the temperature was raised from 
37°C to 65°C with the sealing time constant at 60 min, I dropped by about 40%. Also, 
some of the MERs in the latter case were found to be fragmented in the microscopic field 
of view (data not shown). This may be because high temperatures denature some of the 
proteins in the MER membrane.  
 
We proceeded to study the encapsulation and release of a small molecule from the 
MERs. The molecule is Gd-DTPA, i.e., chelated gadolinium, which is a well-known MRI 
contrast agent. We encapsulated this in the MERs and then used MRI to evaluate the 
release profile. At t = 0, all the solute was in the MERs. As time progressed, some of the 
solute leaked out of the MER membranes into the external solution. The solute 
concentration in the external solution was measured, and the data are shown for the 
cumulative % released vs. time (Figure 4.7). Since sealing time can affect the loading of 
cargo, we obtained these release profiles for two different sealing times: 10 min and 60 





















Figure 4.7. Release of Gd-DTPA from MERs. Data are shown for two different sealing 
times. 
 
Figure 4.7 shows similar release profiles for the two sealing times. Note that 50% 
of the encapsulated Gd-DTPA is released over the first 24 h and more than 80% over 3 
days. However, the amounts encapsulated under the two conditions were different. With 
10 min of sealing time, 0.14 mM Gd-DTPA was encapsulated initially in the MERs. In 
comparison, with 60 min of sealing, 0.21 mM of Gd-DTPA payload was present in the 
MERs, which is 1.5 times higher than the 10 min sample. Thus, a longer sealing time 
allows more solute to be encapsulated, although the rate of solute release seems to be 
independent of the solute concentration.  
 
Targeting MERs to Specific Cells  
The ability to deliver cargo to specific targets is a critical challenge for drug 
delivery. To facilitate this, we attached antibodies to the MERs using the procedure 
shown in Figure 4.1. MERs with DiI and DOPE-biotin were linked to anti-EGFR-biotin 
by an avidin bridge. We then studied the binding of these MERs with anti-EGFR 
antibodies to 15B cells, which are a class of cells that overexpress EGFRs. Our controls 
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were the MERs alone and the MERs with biotin (both also had DiI for visualization by 
fluorescence microscopy. When the controls were combined with 15B cells, there was 
negligible non-specific binding, and the structures were removed easily during the 
washing steps. Thus, no fluorescence is seen in Figures 4.8a and 4.8b. For the MERs with 
anti-EGFR, on the other hand, there was tight binding to the cells, reflected in terms of 
significant red fluorescence in Figure 4.8c. Thus, we see that MERs can be functionalized 
















Figure 4.8. Targeted binding of MERs with 15B cells (which overexpress EGFRs). (a) 
MERs alone, (b) MERs with biotin, c) MERs with anti-EGFR antibodies. The blue 
fluorescence represents the DAPI nucleus counterstain, and the red fluorescence comes 









In this study, we have developed microerythrosome probes as a biocompatible 
and natural carrier that selectively binded to cells that have over-expressed EGFRs on 
their membranes. The MER probes derived from RBCs formed a robust system that 
kept the membrane intact with constant shape and strucutre, and was capable of 
targeting and releasing small molecular cargo in vitro. We have proved that the 
ethanol integration method can be a simple and useful way to achieve the cell surface 
modification, which only involved ethanol and target ligands, without complicated 
chemical reaction. Through the easy intergration method, we decorated the MERs 
with dye, biotin, and even EGFR antibody, which can be further develped for various 
application. As for the drug release function, the MERs reached 50% Gd-DTPA 
release about 24 hrs, and this implies the reduced dose of imaging application for 
MRI. The seletively delivery combined with drug release turned the MER probes into 
an effective cancer theranostic agent. Not only just for the low cost and commrcial 
availability of carrier MERs, but the eventual goal is to synthesize these probes from 
patients’ own blood, which will help minimize immune response and personalize the 






Nano-Erythrosomes and Their Colloidal Properties  
 
5.1. Introduction 
In this Chapter, we study smaller (~ 100 nm) versions of the microerythrosomes 
(MERs), which we term nanoerythrosomes (NERs). The NERs are comparable in size to 
liposomes. As noted in Chapter 3, liposomes are a versatile class of colloidal vehicles for 
pharmaceutical and biomedical applications. They are typically prepared by a high-shear 
process, such as extrusion of a lipid/water mixture through a porous filter, or by 
sonication.65-67 Liposomes typically have nanoscale diameters (~ 100-200 nm) and a 
unilamellar bilayer membrane. They can be made to encapsulate solutes of interest such 
as drugs or proteins, and they can also be endowed with specific biochemical properties 
through moieties attached to the membrane.68-70 
 
However, liposomes also suffer from some problems, especially that of limited 
colloidal stability, i.e., they tend to aggregate or phase-separate when stored at room 
temperature.71 The lack of stability arises because liposomes do not represent a 
thermodynamically stable phase; this is particularly evident from the fact that high-shear 
is needed to form these structures. Colloidal stability can be improved by attaching 
hydrophilic polymers to the liposomal surface – specifically, chains of polyethylene 
glycol (PEG).72 The presence of PEG chains sterically stabilizes the liposomes and thus 
improves their stability;73-75 however, optimal stability is obtained only for certain lengths 
and graft densities of PEGs on the liposomes. Thus, researchers who work with 
56 
 
liposomes still have to confront stability issues. For example, it is customary to either use 
liposomal samples right after preparation or to store these samples in a refrigerator at 4°C 
to improve the stability window. Liposomal stability is also frequently affected by the 
media of choice: for example, stability can be poor for liposomes in the presence of 
serum or cell-growth media.76,77 Finally, liposomes can also be destabilized when the 
sample goes through freeze-thaw cycles.78  
 
As noted in Chapter 4, the idea of creating erythrosomes (also called “ghosts”)  
from erythrocytes dates back to the 1970s.55 Original erythrosomes were about the same 
size as the original erythrocytes (i.e., around 4 µm in diameter). More recently, in the 
1990s, nanoscale analogs of these ghosts were reported by Al-Achi and Boroujerdi79,80 
and by Lejeune et al.81,82; the latter group coined the term “nanoerythrosome” (NER) for 
these structures. NERs were created by these authors by subjecting the microscale ghosts 
to a high-shear process, i.e., sonication or extrusion. The resulting structures had 
nanoscale dimensions (diameters ~ 100 to 200 nm) and are thus directly comparable to 
conventional liposomes.  
 
Although NERs have been known for more than 20 years, they seem to have 
attracted limited interest from the scientific community. One reason is that their physical, 
i.e., colloidal properties, have not been systematically studied. For example, we have 
been unable to find any papers on NERs in traditional journals of colloid science or 
nanoscience; the few papers that have appeared have all been in pharmaceutical 
journals.72,81,83-89 In this paper, we report a systematic study of NERs from a colloidal 
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point of view. We use scattering and microscopic techniques to characterize these 
structures; in particular, the techniques of cryo-transmission electron microscopy (cryo-
TEM) and small-angle neutron scattering (SANS) are used for the first time. We have 
also compared NERs with conventional liposomes prepared from lipids, especially from 
the viewpoint of colloidal stability and solute encapsulation. Our results confirm that 
NERs are unique structures with exceptional stability and that they have significant 
potential for controlled release and targeted drug delivery applications. 
 
5.2. Experimental Section 
Materials. Bovine blood was purchased from Lampire Biological Laboratories. 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); 1,2-dioleoyl-sn-glycero-3-phospho- 
ethanolamine-N-(biotinyl) (sodium salt) (DOPE-Biotin) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DOPE-mPEG) were 
purchased from Avanti Polar Lipids Inc. Cholesterol and Dextran-FITC were obtained 
from Sigma-Aldrich. 1,1'-dioctadecyl- 3,3,3',3'-tetramethyl-indocarbocyanine perchlorate 
(DiI) and 3,3’-Dioctadecyloxacarbocyanine perchlorate (DiO) were purchased from 
Molecular Probes. Phosphate buffer saline (PBS); Fetal bovine serum (FBS); Avidin-
FITC were purchased from Life Technologies.  Dialysis cassettes were purchased from 
Thermo Fisher Scientific Inc. The antibodies, mouse anti-EGFR (sc-120) and 
corresponding mouse IgG2a (sc-3878 ) control, were purchased from Santa Cruz 
Biotechnology, CA. Microbial transglutaminase (mTG)90 and Protein G91 were provided 




Nanoerythrosome Preparation. The procedure for preparing NERs was described 
schematically in Figure 5.1. This procedure is adapted from that used in previous 
studies89,92 with some modifications. First, 100 mL of bovine whole blood was taken, and 
RBCs were separated from it by centrifuging three times (2,000 rpm, 10 min). Between 
each step, the RBCs at the bottom of the tube were washed and resuspended in PBS. 
After the third step, the RBCs were transferred to a hypotonic solution to remove the 
hemoglobin. The hypotonic solution was composed of PBS with 0.14 M NaCl, 10 mM 
Na-phosphate, and 3 mM KCl. The RBCs were incubated in the hypotonic PBS for 5 min 
on ice. This was then transfered to an ultracentrifuge (Beckman SW28) and run at 12,000 
rpm for 10 min at 4°C. The pellet (cells with hemoglobin removed) was collected and 
resuspended in the hypotonic PBS, and this process was repeated thrice. Subsequently, 
the sediment was resuspended in cold PBS and ultracentrifuged at 20,000 rpm for 10 min 
at 4°C; this was again repeated thrice. The final pellet contains the washed MERs (Figure 
5.1c). These MERs were placed in PBS (pH of 7.4) and this solution was ultrasonicated 
using a probe sonicator (Qsonica) at 47.5 W for 15 min to give the NERs. 
 
Liposome Preparation. Two types of liposomes were prepared according to previous 
procedures.67 Bare liposomes contained a mixture of DPPC:Cholesterol = 60:40 (molar 
ratio). PEGylated liposomes employed a mixture of DPPC: Cholesterol: DOPE-mPEG = 
55:40:5 (molar ratio). The pertinent lipid mixture was dissolved in chloroform and a dried 
film was formed by evaporating the solvent with a dry nitrogen stream, followed by 
vacuum desiccation for 24 h. The lipid film was rehydrated with PBS and stirred at 60°C 
for 2 h. The mixture was then ultrasonicated at 47.5 W for 15 min using a probe sonicator 
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(Qsonica) to give liposomes. Samples were maintained at 4°C before experiments. The 
total lipid concentration in both the final samples was 6 mM. 
 
Cell and Particle Count. The number densities of RBCs and MERs (microscale 
structures) were determined using a hemocytometer (Fisher Scientific). Trypan blue was 
used to provide contrast to the structures before the counts were taken. 
 
Size Measurement. Sizes of nanostructures were measured by Dynamic Light Scattering 
(DLS) at 25°C using a Photocor-FC instrument. The instrument has a 5 mW laser light 
source at 633 nm, and the scattering angle was fixed at 90°. All measurements were done 
in triplicate. 
 
Zeta Potential Measurements. Zeta potentials of the various nanostructures were 
measured by a Laser Doppler Velocimetry technique using a Malvern Zetasizer 
NanoZS90 at a 90° scattering angle. Samples were placed in disposable polystyrene 
cuvettes. All measurements were done in triplicate. 
 
Cryo-Transmission Electron Microscopy (Cryo-TEM). C-Flat holey carbon grids with 
a hole size of 1.2 µm were purchased from Electron Microscopy Sciences. Grids bearing 
aqueous solutions of the nanostructures were plunged into liquid ethane (–183°C) using a 
Gatan CryoPlunge3, so as to form vitrified specimens. The samples were thereafter 




Small-Angle Neutron Scattering (SANS). Measurements were made on the NG-7 (30 
m) beamline at NIST in Gaithersburg, MD. Neutrons with a wavelength of 6 Å were 
selected. Three sample-detector distances were used to probe a range of scattering vectors 
from 0.004 to 0.4 Å-1. Samples were studied in 2 mm quartz cells at 25°C. The 
scattering spectra were corrected and placed on an absolute scale using calibration 
standards provided by NIST. The data are shown for the radially averaged intensity I as a 
function of the scattering vector q = (4π/λ)sin(θ/2), where λ is the neutron wavelength and 
 is the scattering angle. 
 
Stability Tests. To assess colloidal stability, the two liposome samples and the NERs 
were first studied in the presence of FBS. 1 mL of FBS was added to 2 mL of both 
liposomes and NERs samples under 4°C incubation. Sizes were measured periodically by 
DLS. Next, the same samples were subjected to freeze-thaw cycling. During each cycle, 
the samples were frozen at –20°C for 24 h and then thawed at room temperature for 2 h. 
Size changes were measured by DLS after every cycle. All measurements were 
conducted in triplicate. 
 
Solute Encapsulation. To encapsulate the solute (dextran-FITC) in the NERs, the 
following procedure was used. The starting point was with the pellet of MERs, which 
was obtained as described above. This pellet was combined with 1 mg/mL of the solute in 
PBS, followed by sonication as above. This converts the MERs to NERs and the solute is 
internalized during this process. The next step was to “reseal” the disrupted NER 
membranes to ensure that the solute remains inside. For this, the sample was subjected to 
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a freeze-anneal-thaw cycle. That is, the sample was cooled to 4°C, then immediately 
transferred to a water bath at 37°C and annealed at that temperature for 40 min, then 
cooled back to room temperature. At the end of this cycle, we have “sealed” NERs 
containing the solute, but there is also free solute in the outer solution. To remove free 
solute, the solution was purified using size-exclusion chromatography (SEC), i.e., by 
passing it through a 1  20 cm column packed with Sephadex G50 resin (from Sigma-
Aldrich). The same dextran-FITC solute was also encapsulated in the PEGylated 
liposomes. In this case, 1 mg/mL of the solute was added to the solution used to rehydrate 
the lipid film. The mixture was sonicated as before and then purified by SEC using the 
same column as above. 
 
Solute Release Studies. Release of the dextran-FITC solute from the liposomes and the 
NERs was measured as follows. First, 3 mL of the pertinent sample was injected into the 
dialysis cassette, which was then placed into a large flask containing 1 L of PBS buffer 
(see Figure 5.6). The buffer was replaced with fresh buffer every 1 h at the outset and 
thereafter every 4 h. 120 µL of sample was collected periodically from the dialysis bag 
and the fluorescence intensity of solute in the sample was measured by a SpectraMax M2 
spectrometer (Molecular Devices) (Ex: 492 nm, Em: 518 nm). These were converted to 
concentrations using a standard curve. As the solute is released into the external buffer, 
the solute concentration in the bag keeps decreasing. These data were normalized into 




Antibody Conjugation. To conjugate the antibody to NERs, the following procedure 
was used, as shown schematically in Figure 5.7. For this, stock solutions of recombinant 
glutamine-tagged protein G (50 g/mL) and mTG enzyme (1 unit/mL) were obtained 
from the Bentley lab. First, protein G was covalently linked to the NERs using mTG 
(Figure 5.7). To accomplish this, final concentration of 2.5 g/mL of the protein G 
solution was combined with 1 mL of NERs, and then 4  10-3 unit/mL of the mTG 
solution was added. The mixture was subjected to mild shaking at room temperature for 
30 min. Then the NERs with protein G were washed and purified with 100 kDa cutoff 
centrifugal filter tube (EMD Millipore) to remove free protein G. They were resuspended 
in PBS and then 1014 of antibody molecules were added. This mixture was incubated 
overnight at 4°C under mild shaking. Antibody-laden NERs were then purified by 
centrifugation as above. For visualization by fluorescence microscopy, the same NERs 
were also tagged with a fluorescent lipid dye called DiI. This was done during the NER 
formation process: 2 µM DiI was dissolved in ethanol, and 20 µL of this solution was 
added to 1 mL of the MERs, followed by sonication to yield NERs.    
 
Cell Lines. SCCHN 15B cells were provided by Dr Jennifer Grandis (University of 
Pittsburgh). Cells were cultured in RPMI-1640 medium with 10% FBS and 1% L-
glutamine (from Sigma-Aldrich). Cells were maintained at 37°C in 5% CO2.  
 
Cell Targeting Studies. 104 15B cells were seeded onto an 8 well chamber slide at 37°C. 
Cells were propagated to 80% confluency (typically overnight). Then, RPMI medium 
containing 1% bovine serum albumin (BSA) was added to the cells for 30 min. The BSA 
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eliminates non-specific binding of the antibodies to the cells. Two NER samples were 
studied, one with the mouse IgG2a control antibody and the other with the mouse anti-
EGFR antibody. Both NERs were also tagged with DiI. 100 µL of each sample was 
added to separate wells containing the 15B cells and left to incubate for 30 min. 
Thereafter, the cells were washed three times with PBS to remove unbound 
nanostructures. The samples were then fixed with 2% paraformaldehyde. Cells were then 
stained with 4′,6′-diamidino-2-phenylindole (DAPI) (EMD Chemicals), which is a dye 
that binds to the nuclei in the cells. Then the cells were visualized under a fluorescence 
microscope.  
 
5.3. Results and Discussion 
Preparation of Nanoerythrosomes (NERs)  
The procedure for preparing NERs is shown in Figure 5.1. We use bovine blood, which 
has a hematocrit, i.e., volume fraction of erythrocytes, of about 20% (in human blood, the 
hematocrit is about 40%). In terms of number density, we measured the concentration 
(using a cytometer) of erythrocytes in the blood used here to be about 3  109 cells/mL. 
Erythrocytes were separated from the white cells, platelets, and serum by centrifugation 
(Figure 5.1a), i.e., by exploiting differences in density between the different components. 
The separated erythrocytes were then placed in a hypotonic phosphate-buffered saline 
(PBS) solution. This induced the hemoglobin in the cells to be leached out due to the 
osmotic gradient between the cells and the solution (Figure 5.1b). The process was 
carried out over a couple of cycles, and at the end, the pellet at the bottom of the 
centrifuge tube contains the cells without hemoglobin, which have a characteristic pink or 
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white color (Figure 5.1c). These are the erythrosomes, having diameters around 3 to 4 
µm, and they can be resuspended as a stable dispersion either in deionized (DI) water or 
in a buffer (PBS). The concentration of erythrosomes measured by the cytometer was 1 – 
1.5  109 /mL, i.e., the yield was between 30 to 50%. To reduce their size to the 
nanoscale, we subjected the dispersion of erythrosomes to high shear using a tip sonicator 
for 15 min (Figure 5.1d). This resulted in a stable dispersion of empty NERs with sizes 
(see below) around 100 nm. The mass concentration of NERs in the final sample was 























Figure 5.1. Preparation of ERs and NERs from bovine whole blood. Red cells were a) 
separated, burst via hypotonic PBS to cause hemoglobin release, and b) purified via 
ultracentrifugation to remove the hemoglobin in the supernatant. c) Unlysed ERs are in 




Characterization of NERs 
NER sizes were characterized using dynamic light scattering (DLS). DLS yields 
the hydrodynamic diameter (Dh) of particles assuming that the particles are discrete and 
non-interacting. Figure 5.2 plots the Dh of NERs in two media: DI water and PBS. In 
both cases, the NERs have a diameter ~ 105–110 nm and this size remains approximately 
constant over more than two weeks of observation. Thus, the NERs show excellent 
colloidal stability. The sizes of NERs are comparable to those of typical liposomes made 
by extrusion. We found no significant effect of sonication speed or time on NER size: for 
example, sonication times between 3 and 15 min gave identical NER sizes (data not 
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Figure 5.2. Sizes (hydrodynamic diameters from DLS) of NERs over a period of two 




shown). In comparison, liposomes typically become smaller if they are sonicated for 
longer times or at higher shear rates.  
 
Next, the surface charge densities of NERs were measured using zeta potential 
measurements. The zeta potential was found to be around –30 to –40 mV, which 
indicates a fairly strong negative charge on these structures. The membranes of bovine 
NERs are expected to consist of phospholipids (~ 50%), cholesterol (~ 25%) and 
membrane proteins (~ 25%). The net negative charge may arise from anionic 
phospholipids as well as from anionic membrane proteins. The magnitude of this charge 
is probably high enough to ensure colloidal stability of the NERs via electrostatic 
repulsions alone. But in addition, NERs are also expected to be sterically stabilized by 
hydrophilic sugar side-chains, attached to either the lipids or the proteins on the external 
leaflet of the bilayer membrane.  
 
 
The morphology of the NERs was then investigated by cryo-TEM. In this 
technique, the structure in an aqueous colloidal dispersion is preserved by rapid 
vitrification. Cryo-TEM has been extensively used on liposomes previously, but to our 
knowledge, not thus far on NERs. Figure 5.3a shows a typical cryo-TEM image of NERs 
suspended in DI water. Most of the structures appear in the image as circles with a thin, 
dark shell: these correspond to spherical, unilamellar vesicles. The spherical vesicles are 
by far the most common structure in this sample, but a few other morphologies are also 
seen. In Figure 5.3a, we see a few dark lines, which correspond to flat, disklike vesicles, 
observed edgewise. Also, the arrow indicates one instance of a biconcave disk with a 
unilamellar membrane; this is the shape usually associated with erythrocytes. Vesicles 
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that deviate from the unilamellar structure are also seen sometimes, including a 
concentric bilamellar vesicle (Figure 5.3b), and instances of two or three unilamellar 
vesicles inside a larger unilamellar vesicle (Figure 5.3c, 5.3d). For the most part, 
individual structures range in diameter from 90–120 nm, which is broadly consistent with 




Figure 5.3. Cryo-TEM images of NERs. a) In isotonic solution, most NERs are 
unilamellar vesicles with sizes around 100 nm. In rare cases, NERs may also have two 
concentric membranes (b), or vesicle-in-vesicle structures: (c) and (d). NERs in 




The previous cryo-TEM images were for NERs in DI water, and in this hypotonic 
environment, the NERs tend to swell. We also obtained cryo-TEM images for NERs in 
PBS buffer. In this environment, which is hypertonic in the case of the empty NERs, a 
majority of the NERs adopt a biconcave structure (Figure 5.3e, 5.3f). This is consistent 
with the known behavior of erythrocytes, which are biconcave in an isotonic medium, but 
swell into a more spherical geometry in hypotonic media. Note that between a biconcave 
disk and an equivalent sphere, the hydrodynamic diameter is expected to be identical, 
since Dh is dictated by the largest dimension of the object. This explains why similar Dh 
values were measured by DLS for the NERs in water and in PBS. The biconcave 
structure of the NERs can be clearly seen in the closeup image (Figure 5.3f). Note that, 
even after the micron-sized erythrocytes have been converted into nano-sized NERs, this 
biconcave structure is still retained! While the exact origin of biconcavity in erythrocytes 
is not established, it is generally attributed to the presence of a cytoskeletal network 
(made of the proteins spectrin and ankyrin) that is anchored to the bilayer membrane of 
the cells.93 Presumably, this network is able to withstand the processing steps (osmotic 
shock and sonication) and remains intact in the NERs, giving them their characteristic 
shape.             
 
 
We also studied NERs using SANS. For this, we prepared a pellet of the micron-
sized erythrosomes as before and then suspended these in deuterium oxide (D2O). This 
suspension was then sonicated to obtain the NERs. The use of D2O ensures sufficient 
contrast between the scattering objects and the solvent under SANS. The scattered 
intensity I in SANS is measured as a function of the scattering vector q. For a dilute 
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dispersion of weakly interacting vesicles, the intensity I(q) can be accounted purely in 
terms of the form factor P(q) of the scatterers (i.e., the structure factor S(q)  1). In turn, 
I(q) is given by the following expression for the case where the vesicle radius R is large 
relative to the thickness t of the bilayer membrane: 
                                 




( ) ~ 4 sin
t
I q R qR
q
 
                                             (5.1) 
Eq (5.1) indicates that I(q) for such vesicles should show a q–2 decay in the low q range. 
SANS data are plotted in Figure 5.4 for NERs at a concentration of 18 mg/mL in D2O. As 
expected, we find that the intensity I follows a slope of –2 at low and moderate q. Such a 
plot is indeed characteristic of unilamellar vesicles. (If the vesicles were multilamellar, 
we would see additional peak(s) at moderate q, corresponding to the interlamellar 
spacing.) The above SANS data is not sensitive to the overall size of the vesicles because 













Figure 5.4. SANS spectra for NERs in D2O. The intensity I follows a slope of –2 at low 




it falls outside the window of size scales probed by neutrons. However, it permits 
accurate estimation of the bilayer membrane thickness t. This value can be determined by 
plotting the data in a cross-sectional Guinier plot, i.e., a plot of ln(Iq2) vs. q2, which yields 
a straight line with a slope = t2/12 (this is equivalent to fitting eq 1 to the data). From this, 
we estimate t  4.5 nm for the NERs. Our result matches with previous measurements of t 
for erythrocyte membranes, both human and animal, which have reported values of t 
around 4 nm.  
 
Stability of NERs Compared to Liposomes 
Our studies using SANS and cryo-TEM reveal that the structure of NERs is quite 
comparable to that of liposomes (both are unilamellar vesicles). Figure 5.2 also showed 
that the NERs are stable structures, i.e., they exhibit approximately the same size over 
several days. We now compare in more detail the stability of NERs against that of 
liposomes. First, we prepared conventional liposomes using the phospholipid DPPC and 
cholesterol. DPPC has two palmitoyl (C16, saturated) tails and a zwitterionic 
phosphocholine headgroup. Since DPPC is zwitterionic and cholesterol is uncharged, 
DPPC/cholesterol liposomes have a negligible surface charge. Next, we prepared 
liposomes with PEG surface moieties by combining DPPC, cholesterol, and a third lipid, 
DOPE-mPEG. The latter has two oleyl (C18, unsaturated) tails and an anionic 
phosphoethanol-amine headgroup attached to a PEG moiety of molecular weight 2000 
Da. The anionic headgroups of DOPE-mPEG impart a net negative charge to the 




Figure 5.5a shows the normalized size of the three sets of structures over a period 
of time. Here, each sample is studied in the presence of serum, which is the solution 
component of blood that is rich in proteins and salts. Serum contains a variety of proteins, 
especially those that are a part of the immune system such as antibodies. The stability of 
nanostructures in serum is particularly important for drug-delivery applications. At time t 
= 0 in serum, all three structures had mean diameters around 100 nm, and this was also 
their diameter in aqueous buffer. The zeta potentials of the three in serum were measured 
to be 0.4 mV, –48 mV, and –38 mV, for the bare liposomes, PEGylated liposomes, and 
the NERs, respectively. Figure 5.5a shows that the bare liposomes are relatively unstable, 
with their size increasing by a factor of about 2.5 over the first 24 h in serum (this is 
indicative of aggregation into larger structures). Moreover, the liposome samples 
exhibited a precipitate at the bottom of the vial within 4 h of preparation. In comparison, 
both the PEGylated liposomes and the NERs remained stable (no change in size) over a 
period of 96 h. The higher stability of the latter two correlates with their more negative 
surface charge as well as the presence of steric-stabilizing moieties attached to the 
membrane. As mentioned, the stabilizing moieties in the case of the NERs are expected 
to be hydrophilic sugars attached to membrane proteins or lipids.  
 
Another issue is the stability of nanostructures to freeze-thaw cycling. During 
freezing, ice crystals can form inside a liposome and the expansion of ice can rupture the 
membrane. When the sample is thawed, ideally the liposome should revert to its original 
size and structure. We subjected the three samples from above to a number of freeze-
thaw cycles and measured their size at the end of each cycle. The results in Figure 5.5b 
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reveal that the NERs are much more stable to freeze-thaw cycling than the bare or 
PEGylated liposomes. In the latter two cases, a precipitate was found in each sample after 
just one freeze-thaw cycle and the precipitation worsened with each such cycle. In the 
case of the NERs, only slight precipitation was found and that too only after 4 cycles. 
Freeze/Thaw
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Figure 5.5. (a) Stability of NERs compared to liposomes or PEG-conjugated liposomes. 
(a) in serum; (b) in buffer, following freeze/thaw cycling. Filled points in (b) imply that 




Also, the size of the bare liposomes and PEGylated liposomes left in solution 
significantly increased upon freeze-thaw cycling, indicating aggregation, whereas the size 
of the NERs remained relatively constant even after 5 such cycles. We speculate that the 
presence of the spectrin-ankyrin filamentous network attached to the NER membrane is 
responsible for the greater stability of the NERs.  
 
Solute Encapsulation in NERs and Subsequent Release  
Liposomes are used in drug delivery because of their ability to encapsulate solutes 
in their aqueous interior and release them slowly into the external environment. We now 
examine whether similar solute encapsulation and release can be done with NERs. As a 
solute, we chose dextran-FITC, i.e., the polysaccharide dextran (molecular weight ~ 
4,000 Da) attached to the fluorescent dye, fluorescein isothiocyanate (FITC). To 
encapsulate the solute in the NERs, we first added the solute to the erythrosome 
suspension at room temperature and then sonicated the sample. The shear from sonication 
partially ruptures the erythrosome membranes as they rearrange into NERs; during this 
process, some of the solute is internalized. We then subjected the sample to a temperature 
cycle (cool to 4°C, then warm to 37°C, then back to room temperature). During this 
process, the NER membranes are expected to get resealead.62 At this point, the NERs are 
loaded with solute, but free solute is also present in the external solution. To remove the 
free solute, the sample was purified through a size exclusion column. The resulting NERs 
have the solute only inside them, and this sample was then placed in a dialysis cassette 
(this point corresponds to t = 0 for the release experiments). We chose a dialysis 
membrane with a 12 kDa cutoff, which is sufficiently large to allow the dextran-FITC 
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solute to pass through it. Release of solute from the NERs to the external buffer solution 
was then monitored over time by periodically measuring the fluorescence of the solution 
in the dialysis cassette. For comparison with the NERs, a similar experiment was also 
done with liposomes of the phospholipid DPPC (diameter of ~ 100 nm).  
 
Figure 5.6 shows release curves for dextran-FITC from the NERs and the 
liposomes. In the case of the liposomes, the release occurs at a nearly constant rate over 
the first 72 h and thereafter it slows down. In the case of the NERs, the release is slower 
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Figure 5.6. Release of solute (dextran-FITC) encapsulated in NERs or liposomes. The 
samples were placed in dialysis cassettes. The samples were dialyzed against excess of 
PBS buffer for more than four days at room temperature with constant stirring and buffer 
exchanges. Aliquots were withdrawn from the dialysis bag at various time points and 
analyzed for the concentration of solute. 
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over the first 20 h, but then it picks up over the next 20 h, and finally, once about 80% of 
the solute is released, the rate of release slows down again. The NERs release < 10% of 
the solute over the first 10 h compared to the liposomes (~ 25% over the first 10 h). On 
the other hand, 90% of the solute is released by the NERs within 50 h compared to 75 h 
in the case of the liposomes. Note that a clean comparison between NERs and liposomes 
is not easy to make. While the NER sample contains about 3.2  1012 NERs/mL, the 
liposome sample has about 2  1012 liposomes/mL. While the same amount of solute was 
added to both samples at the outset, the encapsulation efficiencies of the two structures 
are also different. The total loading of dextran-FITC (from the readings as t = 0) was 
40 µg/mL in the NERs and 20 µg/mL in the liposomes. Thus, the NERs encapsulate more 
of the solute, although the reason for this is not clear. Overall, we conclude from Figure 
5.6 that NERs can also be used for solute release, much like the liposomes, and that the 
kinetics of solute release is comparable for the two cases.       
  
Targeting Antibody-Conjugated NERs to Specific Cell Types 
Many biomedical applications involve the use of immuno-liposomes, which have 
targeting agents such as antibodies conjugated to their external surface. Such structures 
can target and bind specifically to cells with receptors for the targeting agents (binding is 
usually followed by internalization into the cells through endocytosis). We wanted to 
examine whether such targeting could be carried out with surface-modified NERs. For 
this, we began with an anti-EGFR antibody, where EGFR refers to the epidermal growth 
factor receptor. We then added protein G, which is a protein that has the ability to bind to 
the constant (Fc) region of antibodies. Thereafter, we used an FDA-approved enzyme 
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called microbial transglutaminase (mTG) to conjugate the protein G-antibody complex to 
the membrane of the NERs. mTG is expected to create covalent bonds between the 
protein G portion and membrane proteins on the NERs. By this process, NERs modified 
with anti-EGFR antibodies were obtained, and these were further tagged with a red-























Figure 5.7. Attachment of targeting moieties to NERs, and evaluation of their targeting 
affinity. (Top) Schematic of mTG-mediated conjugation of protein G via glutamine to 
lysine on NERs, followed by spontaneous binding of protein G to the stem of antibodies. 
(Bottom) Fluorescence micrographs of 15B cells (which overexpress EGFR) incubated 
with a) blank, b) liposomes, c) NERs with protein G-IgG2a, d) NERs with protein G-
anti-EGFR. Green represents cell boundaries, blue is DAPI counterstain of nuclei, and 





We then selected the 15B cell line, which is a class of squamous cell carcinoma of 
the head and neck (SCCHN). These cells are known to over-express EGFRs on their 
membranes. The cells and the above NERs were incubated for 30 min, followed by 
washing to remove unbound structures. As a control, we also synthesized NERs with a 
different antibody (mouse IgG2a) that has no affinity for EGFR using the same procedure 
as above. Figure 5.7 shows images from fluorescence microscopy for the two cases. The 
NERs with anti-EGFR antibodies show substantial binding to the 15B cells as seen by the 
significant red fluorescence. In the control case, there is negligible binding of the NERs 
to the 15B cells, as noted from the absence of red fluorescence. These results indicate that 
NERs tagged with antibodies can serve as targeting agents, with the ability to bind to 
specific types of cells. Thus, we again show that NERs can have many of the same 












In this study, we extracted erythrocytes from bovine blood and converted these 
into nanoerythrosomes (NERs). This was done by using osmotic gradients to remove the 
hemoglobin, and then sonicating the empty structures. NERs were found to be 
nanospheres with an average diameter ~ 110 nm, enclosed by a unilamellar bilayer 
membrane of thickness ~ 4.5 nm. Compared to liposomes, NERs show improved 
colloidal stability in buffer and in serum, and are more stable to freeze-thaw cycling. 
Much like liposomes, NERs can encapsulate solutes (small molecules or 
macromolecules) in their aqueous core, and these can be subsequently released by 
diffusion throughthe bilayer. NERs can also be decorated with targeting agents like 
antibodies, and such NERs can bind specifically to cells that have the receptors for the 
antibodies. In other words, NERs have many of the same capabilities as conventional 
liposomes, but with the added advantage of better colloidal stability. This improved 
stability is evidently because many of the membrane proteins and glycolipids attached to 
the blood cell membrane are still intact in the case of the NERs. While the presence of 
these membrane-bound molecules is beneficial in this context, there is also the risk of an 
immune response to these molecules if NERs were injected into a foreign species. 
However, there is the possibility of harvesting NERs from a patient’s own blood. This 
possibility can become more realistic if NER preparation and functionalization can be 
performed at the bedside, possibly using lab-on-a-chip devices. Such NERs may 
potentially offer several benefits including biocompatibility, minimization of immune 




Conclusions and Recommendations 
 
6.1. Project Summary and Principal Contributions 
In this dissertation, we have shown three kinds of delivery carriers which specifically 
recognized head & neck cancer cells. These carriers were developed from biocompatible 
materials with a simple purification process and minimal chemical reactions to facilitate 
scale-up toward clinical usage. The carrier sources come from either biomimetic 
(liposomes – chapter 3) or natural cells (microerythrosomes – chapter 4, 
nanoerythrosomes – chapter 5). An EGFR antibody (Cetuximab) was conjugated onto 
these carriers through a non-covalent or enzymatic method to provide targeting ability for 
drug delivery.    
 
In chapter 3, we described a simple self-assembled liposomal nanocarrier with the 
ability to bind to head & neck cancer cells and display a MRI signal. The construct was 
first formed by DPPC liposomes with MRI contrast (Gd) using a sonication method 
followed by conjugation of EGFR antibody (Cetuximab) to the surface. The nanocarriers 
have a size of 100 nm and show significant stability over two weeks. The stable construct 
can selectively deliver contrast agent to 15B cells with significant MRI contrast as 
displayed in an in vitro study for tracking cancer localization. 
 
In Chapter 4, we reported a natural carrier based on red blood cells (RBCs) called 
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micro erythrosomes (MERs). These MERs display advantages inherited from RBCs, 
including biocompatibility and long term stability. Additionally, the MERs sacrifice their 
contents (e.g. hemoglobins and proteins) to accept therapeutic agents or drugs, which 
allows more agent to be stored within the MER than if a RBC alone was loaded with the 
agent. Furthermore, MERS can be created from a patient’s own blood to yield a 
personalized treatment. Finally, MER membranes, unlike RBCs, are easily functionalized, 
which converts MERs into multifunctional carriers. As a result, the MERs display the 
ability to selectively deliver MRI contrast agent to head & neck cancer cells. 
 
In Chapter 5, we demonstrate the practical application of biomimetic nanocarriers 
derived from RBCs, which are further processed from MERs to yield a nano-sized carrier, 
nanoerythrosomes (NERs). The NERs have a strong skeletal system to maintain their 
structures in a sphere or biconcave structure, and tolerate various deformations. In order 
to minimize toxicity the binding of a targeting antibody to NERs is also processed with 
microbial transglutaminase (mTG), which is FDA approved. Surface functionalized 
NERs also display the ability to encapsulate drug and specifically deliver it to head & 
neck cancer cells in a similar manner to our previously studied ERs. Additionally, NERs 
have a size advantage over MERs displayed by the fact that NERs can accumulate and 
penetrate local areas of tissue due to their smaller size.  
 
We believe the introduction of the above simple, enzymatic formulation of 
biomimetic and natural carrier development will replace the high cost and low 






(Z, Y= alkyl chains)
1-lysophospholipid (1-LPL)
Figure 6.1. Structures of phospholipid and derivative. One acyl chain is removed from 
phospholipid by phospholipase and generates lysophospholipid.  
field of personalized drug delivery systems.  
 
6.2. Recommendations for Future Work 
The work we have done in this dissertation can be further extended and explored for 
more detail and new applications. The following is the recommendations for the future 
work. 
 
6.2.1 Control release of drugs 
In this dissertation, we reported drug release rate for different carriers; the stronger barrier, 
the slower release rate. It could be possible to elongate the drug release time by adjusting 
the lipid ratio for vesicle, or incorporating the crosslinking on the membrane to slow the 
leak. However, it is difficult to accurately control the membrane permeability and the 
stability, especially the natural material. For the drug delivery aspect, sometimes the 
release timing could be an even critical factor for the drug efficiency. Recently, a group of 
second-messenger molecules, which regulated intracellular signaling pathways, shows to 
involve in many physiological and pathological processes. One example is 
dipalmitoylphosphatidylcholine (DPPC). DPPC is hydrolyzed by the enzyme 








Figure 6.2. Glucose oxidase commonly used on food market. a) Glucose oxidase can 
convert glucose into gluconic acid and hydrogen peroxide, b) once the targeted MERs 
attach to the surface of cells, then the product of enzyme may kill cells by hydrogen 
peroxide. 
and produces two secondary-messenger molecules: palmitoyl-lyso-phosphatidyl choline 
(LPC) and palmitic acid (PA), in a 1:1 molar ratio (Figure 6.1).94 Compared to the LPC 
(lysophospholipid), phospholipid tends to form lamellar vesicle, but lysophospholipid is 
similar to surfactant, which may form micelle. Lysophospholipid has been proved that it 
can be used to achieve local mild hyperthermia in tumor and impact drug delivery 
systems due to the sensitivity of low temperature.95,96 As the temperature raising process, 
the liposome may become more porous property to release the drug, and that could be an 
effective control release switch for our lipid formulated erythrosome/nanoerythrosome 
model. 
 
6.2.2 Specific clearance of cancers 
To further evaluate the drug delivery with cancer clearance functionality for MER or 
NER, we can encapsulate some anticancer drug or potential killing reagent in the core of 
them, for example, glucose oxidase (GOx). The glucose oxidase is a commercial 
available enzyme that catalyzes glucose into hydrogen peroxide (H2O2) and gluconic acid 
(Figure 6.2a). Hydrogen peroxide may damage cells through direct oxidation of lipids, 
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proteins and DNA or it can act as a signaling molecule to trigger intracellular pathways 
leading to cell death.97,98 By adapting the similar platform from chapter 4, we can 
encapsulate GOx easily in MERs with resealing method. 15B cells as high EGFR 
expression model are seeded in a 96-wells plate, and incubated with either control MERs 
without targeting function, or the MER probes, both containing glucose oxidase. After 
short incubation time, the unbind MERs should be washed off from the cells and the 
MERs which still bind to the cells will begin to generate hydrogen peroxide by catalyzing 
the glucose in medium. Once the localized concentration is high enough, then the cell 
membrane may get damage or even lethal for the cells. By encapsulating the glucose 
oxidase with the targeting MERs, it may turn the biocompatible carrier into a cancer 
clearance agent (Figure 6.2b).  
 
6.2.3 Animal studies  
Studies in a wide range of animals were foundational and critical for understanding the 
potential impact to human. Particularly, the animal testing helps to ensure the safety of 
carriers/drugs and many other substances. Some of the drugs may only show the 
dangerous effect when combining with the metabolism in the body, while the in vitro 
would not show the toxicity. For the treatment aspect, carriers/drugs may be sensitive to 
the temperature, pH and immune cells in the circulation system, these animal studies will 
further exam for the essential characteristics of our products. That means that between in 
vitro and clinical studies, it’s necessary for testing our system with animal studies in vivo, 
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